false 2023 Q3 0000072331 October 31 P1Y 0000072331 2022-11-01 2023-07-31 0000072331 2023-08-22 xbrli:shares 0000072331 2023-05-01 2023-07-31 iso4217:USD 0000072331 2022-05-01 2022-07-31 0000072331 2021-11-01 2022-07-31 iso4217:USD xbrli:shares 0000072331 2023-07-31 0000072331 2022-10-31 0000072331 us-gaap:CommonStockMember 2022-10-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2022-10-31 0000072331 us-gaap:RetainedEarningsMember 2022-10-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-31 0000072331 us-gaap:TreasuryStockCommonMember 2022-10-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2022-11-01 2023-01-31 0000072331 us-gaap:TreasuryStockCommonMember 2022-11-01 2023-01-31 0000072331 2022-11-01 2023-01-31 0000072331 us-gaap:RetainedEarningsMember 2022-11-01 2023-01-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-11-01 2023-01-31 0000072331 us-gaap:CommonStockMember 2023-01-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2023-01-31 0000072331 us-gaap:RetainedEarningsMember 2023-01-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-31 0000072331 us-gaap:TreasuryStockCommonMember 2023-01-31 0000072331 2023-01-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2023-02-01 2023-04-30 0000072331 us-gaap:TreasuryStockCommonMember 2023-02-01 2023-04-30 0000072331 2023-02-01 2023-04-30 0000072331 us-gaap:RetainedEarningsMember 2023-02-01 2023-04-30 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-02-01 2023-04-30 0000072331 us-gaap:CommonStockMember 2023-04-30 0000072331 us-gaap:AdditionalPaidInCapitalMember 2023-04-30 0000072331 us-gaap:RetainedEarningsMember 2023-04-30 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-30 0000072331 us-gaap:TreasuryStockCommonMember 2023-04-30 0000072331 2023-04-30 0000072331 us-gaap:AdditionalPaidInCapitalMember 2023-05-01 2023-07-31 0000072331 us-gaap:TreasuryStockCommonMember 2023-05-01 2023-07-31 0000072331 us-gaap:RetainedEarningsMember 2023-05-01 2023-07-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-05-01 2023-07-31 0000072331 us-gaap:CommonStockMember 2023-07-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2023-07-31 0000072331 us-gaap:RetainedEarningsMember 2023-07-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-31 0000072331 us-gaap:TreasuryStockCommonMember 2023-07-31 0000072331 us-gaap:CommonStockMember 2021-10-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2021-10-31 0000072331 us-gaap:RetainedEarningsMember 2021-10-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-31 0000072331 us-gaap:TreasuryStockCommonMember 2021-10-31 0000072331 2021-10-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2021-11-01 2022-01-31 0000072331 us-gaap:TreasuryStockCommonMember 2021-11-01 2022-01-31 0000072331 2021-11-01 2022-01-31 0000072331 us-gaap:RetainedEarningsMember 2021-11-01 2022-01-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-11-01 2022-01-31 0000072331 us-gaap:CommonStockMember 2022-01-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0000072331 us-gaap:RetainedEarningsMember 2022-01-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-31 0000072331 us-gaap:TreasuryStockCommonMember 2022-01-31 0000072331 2022-01-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2022-04-30 0000072331 us-gaap:TreasuryStockCommonMember 2022-02-01 2022-04-30 0000072331 2022-02-01 2022-04-30 0000072331 us-gaap:RetainedEarningsMember 2022-02-01 2022-04-30 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-02-01 2022-04-30 0000072331 us-gaap:CommonStockMember 2022-04-30 0000072331 us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0000072331 us-gaap:RetainedEarningsMember 2022-04-30 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-30 0000072331 us-gaap:TreasuryStockCommonMember 2022-04-30 0000072331 2022-04-30 0000072331 us-gaap:AdditionalPaidInCapitalMember 2022-05-01 2022-07-31 0000072331 us-gaap:TreasuryStockCommonMember 2022-05-01 2022-07-31 0000072331 us-gaap:RetainedEarningsMember 2022-05-01 2022-07-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-05-01 2022-07-31 0000072331 us-gaap:CommonStockMember 2022-07-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2022-07-31 0000072331 us-gaap:RetainedEarningsMember 2022-07-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-31 0000072331 us-gaap:TreasuryStockCommonMember 2022-07-31 0000072331 2022-07-31 xbrli:pure 0000072331 us-gaap:EmployeeStockOptionMember 2023-05-01 2023-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2022-05-01 2022-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2022-11-01 2023-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2021-11-01 2022-07-31 0000072331 us-gaap:SubsequentEventMember ndsn:ARAGGroupMember 2023-08-24 iso4217:EUR 0000072331 srt:MinimumMember us-gaap:SubsequentEventMember ndsn:ARAGGroupMember 2023-08-24 0000072331 us-gaap:SubsequentEventMember srt:MaximumMember ndsn:ARAGGroupMember 2023-08-24 0000072331 us-gaap:SubsequentEventMember ndsn:ARAGGroupMember 2023-08-24 2023-08-24 0000072331 ndsn:CyberOpticsCorporationMember 2022-11-03 0000072331 ndsn:CyberOpticsCorporationMember 2022-11-03 2022-11-03 0000072331 us-gaap:TradeNamesMember ndsn:CyberOpticsCorporationMember 2022-11-03 0000072331 us-gaap:TradeNamesMember ndsn:CyberOpticsCorporationMember 2022-11-03 2022-11-03 0000072331 us-gaap:TechnologyBasedIntangibleAssetsMember ndsn:CyberOpticsCorporationMember 2022-11-03 0000072331 us-gaap:TechnologyBasedIntangibleAssetsMember ndsn:CyberOpticsCorporationMember 2022-11-03 2022-11-03 0000072331 us-gaap:CustomerRelationshipsMember ndsn:CyberOpticsCorporationMember 2022-11-03 0000072331 us-gaap:CustomerRelationshipsMember ndsn:CyberOpticsCorporationMember 2022-11-03 2022-11-03 0000072331 2022-11-03 2022-11-03 0000072331 ndsn:NDCTechnologiesMember 2021-11-01 0000072331 ndsn:NDCTechnologiesMember 2021-11-01 2021-11-01 0000072331 us-gaap:TradeNamesMember ndsn:NDCTechnologiesMember 2021-11-01 0000072331 us-gaap:TradeNamesMember ndsn:NDCTechnologiesMember 2021-11-01 2021-11-01 0000072331 us-gaap:TechnologyBasedIntangibleAssetsMember ndsn:NDCTechnologiesMember 2021-11-01 0000072331 us-gaap:TechnologyBasedIntangibleAssetsMember ndsn:NDCTechnologiesMember 2021-11-01 2021-11-01 0000072331 us-gaap:CustomerRelationshipsMember ndsn:NDCTechnologiesMember 2021-11-01 0000072331 us-gaap:CustomerRelationshipsMember ndsn:NDCTechnologiesMember 2021-11-01 2021-11-01 0000072331 us-gaap:NoncompeteAgreementsMember ndsn:NDCTechnologiesMember 2021-11-01 0000072331 us-gaap:NoncompeteAgreementsMember ndsn:NDCTechnologiesMember 2021-11-01 2021-11-01 0000072331 us-gaap:LandMember 2023-07-31 0000072331 us-gaap:LandMember 2022-10-31 0000072331 us-gaap:LandImprovementsMember 2023-07-31 0000072331 us-gaap:LandImprovementsMember 2022-10-31 0000072331 us-gaap:BuildingMember 2023-07-31 0000072331 us-gaap:BuildingMember 2022-10-31 0000072331 us-gaap:MachineryAndEquipmentMember 2023-07-31 0000072331 us-gaap:MachineryAndEquipmentMember 2022-10-31 0000072331 ndsn:EnterpriseManagementSystemsMember 2023-07-31 0000072331 ndsn:EnterpriseManagementSystemsMember 2022-10-31 0000072331 us-gaap:ConstructionInProgressMember 2023-07-31 0000072331 us-gaap:ConstructionInProgressMember 2022-10-31 0000072331 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2023-07-31 0000072331 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2022-10-31 0000072331 ndsn:IndustrialPrecisionSolutionsMember 2022-10-31 0000072331 ndsn:MedicalFluidSystemsMember 2022-10-31 0000072331 ndsn:AdvancedTechnologySolutionsMember 2022-10-31 0000072331 ndsn:IndustrialPrecisionSolutionsMember 2022-11-01 2023-07-31 0000072331 ndsn:MedicalFluidSystemsMember 2022-11-01 2023-07-31 0000072331 ndsn:AdvancedTechnologySolutionsMember 2022-11-01 2023-07-31 0000072331 ndsn:IndustrialPrecisionSolutionsMember 2023-07-31 0000072331 ndsn:MedicalFluidSystemsMember 2023-07-31 0000072331 ndsn:AdvancedTechnologySolutionsMember 2023-07-31 0000072331 us-gaap:CustomerRelationshipsMember 2023-07-31 0000072331 us-gaap:PatentedTechnologyMember 2023-07-31 0000072331 us-gaap:TradeNamesMember 2023-07-31 0000072331 us-gaap:NoncompeteAgreementsMember 2023-07-31 0000072331 us-gaap:OtherIntangibleAssetsMember 2023-07-31 0000072331 us-gaap:CustomerRelationshipsMember 2022-10-31 0000072331 us-gaap:PatentedTechnologyMember 2022-10-31 0000072331 us-gaap:TradeNamesMember 2022-10-31 0000072331 us-gaap:NoncompeteAgreementsMember 2022-10-31 0000072331 us-gaap:OtherIntangibleAssetsMember 2022-10-31 0000072331 us-gaap:PensionPlansDefinedBenefitMember country:US 2021-11-01 2022-07-31 ndsn:segment 0000072331 us-gaap:PensionPlansDefinedBenefitMember country:US 2023-05-01 2023-07-31 0000072331 us-gaap:PensionPlansDefinedBenefitMember country:US 2022-05-01 2022-07-31 0000072331 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-05-01 2023-07-31 0000072331 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-05-01 2022-07-31 0000072331 us-gaap:PensionPlansDefinedBenefitMember country:US 2022-11-01 2023-07-31 0000072331 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-11-01 2023-07-31 0000072331 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-11-01 2022-07-31 0000072331 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-05-01 2023-07-31 0000072331 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-05-01 2022-07-31 0000072331 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-05-01 2023-07-31 0000072331 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-05-01 2022-07-31 0000072331 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-11-01 2023-07-31 0000072331 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-11-01 2022-07-31 0000072331 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-11-01 2023-07-31 0000072331 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-11-01 2022-07-31 0000072331 us-gaap:AccumulatedTranslationAdjustmentMember 2022-10-31 0000072331 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-10-31 0000072331 us-gaap:AccumulatedTranslationAdjustmentMember 2022-11-01 2023-07-31 0000072331 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-11-01 2023-07-31 0000072331 us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-31 0000072331 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-07-31 0000072331 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2022-11-01 2023-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2022-11-01 2023-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2023-05-01 2023-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2022-05-01 2022-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2021-11-01 2022-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2022-10-31 0000072331 us-gaap:EmployeeStockOptionMember 2023-07-31 0000072331 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2022-11-01 2023-07-31 0000072331 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-11-01 2022-07-31 0000072331 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-11-01 2022-07-31 0000072331 ndsn:RestrictedSharesAndRestrictedShareUnitsMember srt:MinimumMember 2022-11-01 2023-07-31 0000072331 ndsn:RestrictedSharesAndRestrictedShareUnitsMember srt:MaximumMember 2022-11-01 2023-07-31 0000072331 us-gaap:RestrictedStockMember 2022-11-01 2023-07-31 0000072331 us-gaap:RestrictedStockMember 2022-10-31 0000072331 us-gaap:RestrictedStockMember 2023-07-31 0000072331 us-gaap:RestrictedStockMember 2023-05-01 2023-07-31 0000072331 us-gaap:RestrictedStockMember 2022-05-01 2022-07-31 0000072331 us-gaap:RestrictedStockMember 2021-11-01 2022-07-31 0000072331 us-gaap:RestrictedStockUnitsRSUMember 2022-10-31 0000072331 us-gaap:RestrictedStockUnitsRSUMember 2022-11-01 2023-07-31 0000072331 us-gaap:RestrictedStockUnitsRSUMember 2023-07-31 0000072331 us-gaap:RestrictedStockUnitsRSUMember 2023-05-01 2023-07-31 0000072331 us-gaap:RestrictedStockUnitsRSUMember 2022-05-01 2022-07-31 0000072331 us-gaap:RestrictedStockUnitsRSUMember 2021-11-01 2022-07-31 0000072331 us-gaap:PerformanceSharesMember 2022-11-01 2023-07-31 0000072331 ndsn:GrantDateOneMember us-gaap:PerformanceSharesMember 2023-07-31 0000072331 ndsn:GrantDateTwoMember us-gaap:PerformanceSharesMember 2023-07-31 0000072331 ndsn:GrantDateThreeMember us-gaap:PerformanceSharesMember 2023-07-31 0000072331 ndsn:GrantDateTwoMember us-gaap:PerformanceSharesMember 2022-07-31 0000072331 ndsn:GrantDateOneMember us-gaap:PerformanceSharesMember 2022-07-31 0000072331 ndsn:GrantDateThreeMember us-gaap:PerformanceSharesMember 2022-07-31 0000072331 us-gaap:PerformanceSharesMember 2023-05-01 2023-07-31 0000072331 us-gaap:PerformanceSharesMember 2022-05-01 2022-07-31 0000072331 us-gaap:PerformanceSharesMember 2021-11-01 2022-07-31 0000072331 us-gaap:PerformanceSharesMember 2023-07-31 0000072331 ndsn:EmployeeDeferredCompensationPlanMember 2022-11-01 2023-07-31 0000072331 ndsn:EmployeeDeferredCompensationPlanMember 2023-05-01 2023-07-31 0000072331 ndsn:EmployeeDeferredCompensationPlanMember 2022-05-01 2022-07-31 0000072331 ndsn:EmployeeDeferredCompensationPlanMember 2021-11-01 2022-07-31 0000072331 us-gaap:DeferredCompensationShareBasedPaymentsMember srt:DirectorMember 2022-10-31 0000072331 us-gaap:DeferredCompensationShareBasedPaymentsMember srt:DirectorMember 2022-11-01 2023-07-31 0000072331 us-gaap:DeferredCompensationShareBasedPaymentsMember srt:DirectorMember 2023-07-31 0000072331 ndsn:EmployeeDeferredCompensationPlanMember srt:DirectorMember 2023-05-01 2023-07-31 0000072331 ndsn:EmployeeDeferredCompensationPlanMember srt:DirectorMember 2022-05-01 2022-07-31 0000072331 ndsn:EmployeeDeferredCompensationPlanMember srt:DirectorMember 2022-11-01 2023-07-31 0000072331 ndsn:EmployeeDeferredCompensationPlanMember srt:DirectorMember 2021-11-01 2022-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:IndustrialPrecisionSolutionsMember 2023-05-01 2023-07-31 0000072331 ndsn:MedicalAndFluidSolutionsMember us-gaap:OperatingSegmentsMember 2023-05-01 2023-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:AdvancedTechnologySolutionsMember 2023-05-01 2023-07-31 0000072331 us-gaap:CorporateNonSegmentMember 2023-05-01 2023-07-31 0000072331 us-gaap:OperatingSegmentsMember 2023-05-01 2023-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:IndustrialPrecisionSolutionsMember 2022-05-01 2022-07-31 0000072331 ndsn:MedicalAndFluidSolutionsMember us-gaap:OperatingSegmentsMember 2022-05-01 2022-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:AdvancedTechnologySolutionsMember 2022-05-01 2022-07-31 0000072331 us-gaap:CorporateNonSegmentMember 2022-05-01 2022-07-31 0000072331 us-gaap:OperatingSegmentsMember 2022-05-01 2022-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:IndustrialPrecisionSolutionsMember 2022-11-01 2023-07-31 0000072331 ndsn:MedicalAndFluidSolutionsMember us-gaap:OperatingSegmentsMember 2022-11-01 2023-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:AdvancedTechnologySolutionsMember 2022-11-01 2023-07-31 0000072331 us-gaap:CorporateNonSegmentMember 2022-11-01 2023-07-31 0000072331 us-gaap:OperatingSegmentsMember 2022-11-01 2023-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:IndustrialPrecisionSolutionsMember 2021-11-01 2022-07-31 0000072331 ndsn:MedicalAndFluidSolutionsMember us-gaap:OperatingSegmentsMember 2021-11-01 2022-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:AdvancedTechnologySolutionsMember 2021-11-01 2022-07-31 0000072331 us-gaap:CorporateNonSegmentMember 2021-11-01 2022-07-31 0000072331 us-gaap:OperatingSegmentsMember 2021-11-01 2022-07-31 0000072331 ndsn:AmericasExcludingUnitedStatesMember 2023-05-01 2023-07-31 0000072331 ndsn:AmericasExcludingUnitedStatesMember 2022-05-01 2022-07-31 0000072331 ndsn:AmericasExcludingUnitedStatesMember 2022-11-01 2023-07-31 0000072331 ndsn:AmericasExcludingUnitedStatesMember 2021-11-01 2022-07-31 0000072331 srt:EuropeMember 2023-05-01 2023-07-31 0000072331 srt:EuropeMember 2022-05-01 2022-07-31 0000072331 srt:EuropeMember 2022-11-01 2023-07-31 0000072331 srt:EuropeMember 2021-11-01 2022-07-31 0000072331 ndsn:AsiaPacificExcludingJapanMember 2023-05-01 2023-07-31 0000072331 ndsn:AsiaPacificExcludingJapanMember 2022-05-01 2022-07-31 0000072331 ndsn:AsiaPacificExcludingJapanMember 2022-11-01 2023-07-31 0000072331 ndsn:AsiaPacificExcludingJapanMember 2021-11-01 2022-07-31 0000072331 us-gaap:FairValueMeasurementsRecurringMember 2023-07-31 0000072331 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2023-07-31 0000072331 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-07-31 0000072331 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-07-31 0000072331 us-gaap:FairValueMeasurementsRecurringMember 2022-10-31 0000072331 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2022-10-31 0000072331 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-10-31 0000072331 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-10-31 0000072331 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2023-07-31 0000072331 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:LongMember 2023-07-31 0000072331 currency:GBP us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2023-07-31 0000072331 currency:GBP us-gaap:ForeignExchangeContractMember us-gaap:LongMember 2023-07-31 0000072331 currency:JPY us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2023-07-31 0000072331 currency:JPY us-gaap:ForeignExchangeContractMember us-gaap:LongMember 2023-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:ShortMember currency:MXN 2023-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:MXN us-gaap:LongMember 2023-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:ShortMember currency:HKD 2023-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:LongMember currency:HKD 2023-07-31 0000072331 currency:SGD us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2023-07-31 0000072331 currency:SGD us-gaap:ForeignExchangeContractMember us-gaap:LongMember 2023-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:ShortMember currency:AUD 2023-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:AUD us-gaap:LongMember 2023-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:ShortMember currency:TWD 2023-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:TWD us-gaap:LongMember 2023-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:ShortMember srt:OtherCurrencyMember 2023-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:LongMember srt:OtherCurrencyMember 2023-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2023-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:LongMember 2023-07-31 0000072331 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2022-07-31 0000072331 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:LongMember 2022-07-31 0000072331 currency:GBP us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2022-07-31 0000072331 currency:GBP us-gaap:ForeignExchangeContractMember us-gaap:LongMember 2022-07-31 0000072331 currency:JPY us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2022-07-31 0000072331 currency:JPY us-gaap:ForeignExchangeContractMember us-gaap:LongMember 2022-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:ShortMember currency:HKD 2022-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:LongMember currency:HKD 2022-07-31 0000072331 currency:SGD us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2022-07-31 0000072331 currency:SGD us-gaap:ForeignExchangeContractMember us-gaap:LongMember 2022-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:ShortMember currency:AUD 2022-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:AUD us-gaap:LongMember 2022-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:ShortMember srt:OtherCurrencyMember 2022-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:LongMember srt:OtherCurrencyMember 2022-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2022-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:LongMember 2022-07-31 0000072331 currency:EUR ndsn:TermLoanFacilityAgreementDue2024Member 2023-07-31 0000072331 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-07-31 0000072331 us-gaap:OtherAssetsMember 2023-07-31 0000072331 us-gaap:AccruedLiabilitiesMember 2023-07-31 0000072331 us-gaap:OtherNoncurrentLiabilitiesMember 2023-07-31 0000072331 ndsn:RevolvingCreditAgreementDue2028Member 2023-07-31 0000072331 ndsn:RevolvingCreditAgreementDue2028Member 2022-10-31 0000072331 ndsn:SeniorNotesDue20232025Member 2023-07-31 0000072331 ndsn:SeniorNotesDue20232025Member 2022-10-31 0000072331 ndsn:SeniorNotesDue20232027Member 2023-07-31 0000072331 ndsn:SeniorNotesDue20232027Member 2022-10-31 0000072331 ndsn:SeniorNotesDue20232030Member 2023-07-31 0000072331 ndsn:SeniorNotesDue20232030Member 2022-10-31 0000072331 ndsn:TermLoanDue2026Member 2023-07-31 0000072331 ndsn:TermLoanDue2026Member 2022-10-31 0000072331 ndsn:EuroLoanDue2023Member 2023-07-31 0000072331 ndsn:EuroLoanDue2023Member 2022-10-31 0000072331 2023-06-06 0000072331 ndsn:RevolvingCreditAgreementDue2028Member 2023-06-06 0000072331 ndsn:TermLoanDue2026Member 2023-06-06 0000072331 srt:MinimumMember ndsn:RevolvingCreditAgreementDue2028Member 2023-06-06 0000072331 ndsn:RevolvingCreditAgreementDue2028Member srt:MaximumMember 2023-06-06 0000072331 us-gaap:RevolvingCreditFacilityMember 2023-07-31 0000072331 ndsn:RevolvingCreditAgreementDue2024Member 2019-04-30 0000072331 ndsn:RevolvingCreditAgreementDue2024Member 2019-04-01 2019-04-30 0000072331 ndsn:RevolvingCreditAgreementDue2024Member ndsn:SwingLineLoansMember 2019-04-30 0000072331 ndsn:SeniorNotesDue20232025Member 2022-11-01 2023-07-31 0000072331 ndsn:SeniorNotesDue20232027Member 2022-11-01 2023-07-31 0000072331 ndsn:SeniorNotesDue20232030Member 2022-11-01 2023-07-31 0000072331 ndsn:StephenPLovassMember 2022-11-01 2023-07-31 0000072331 ndsn:StephenPLovassMember 2023-07-31

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 31, 2023
OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission file number 0-7977
____________________________________________________
NORDSON CORPORATION
(Exact name of registrant as specified in its charter)
___________________________________________________
Ohio
(State or other jurisdiction of incorporation or organization)
28601 Clemens Road
Westlake, Ohio
(Address of principal executive offices)
34-0590250
(I.R.S. Employer Identification No.)
44145
(Zip Code)
(440) 892-1580
(Registrant's Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class |  | Trading Symbol(s) |  | Name of Each Exchange On Which Registered
Common Shares, without par value |  | NDSN |  | Nasdaq Stock Market LLC

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes x No o
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ |  | Accelerated filer | ☐
Non-accelerated filer | ☐ |  | Smaller reporting company | ☐
Emerging growth company | ☐ |  |  |

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: Common Shares, without par value as of August 22, 2023: 57,014,497

Table of Contents

PART I – FINANCIAL INFORMATION | 3
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) | 3
Condensed Consolidated Statements of Income | 3
Consolidated Statements of Comprehensive Income | 4
Consolidated Balance Sheets | 5
Consolidated Statements of Shareholders' Equity | 6
Condensed Consolidated Statements of Cash Flows | 8
Notes to Condensed Consolidated Financial Statements | 9
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 24
Overview | 24
Critical Accounting Policies and Estimates | 24
Results of Operations | 25
Financial Condition | 28
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 29
ITEM 4. CONTROLS AND PROCEDURES | 29
PART II – OTHER INFORMATION | 30
ITEM 1. LEGAL PROCEEDINGS | 30
ITEM 1A. RISK FACTORS | 30
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 30
ITEM 5. OTHER INFORMATION | 30
ITEM 6. EXHIBITS | 31
SIGNATURE | 32

Page 2

Table of Contents
Nordson Corporation
Part I – FINANCIAL INFORMATION

ITEM 1. | FINANCIAL STATEMENTS (UNAUDITED)

Condensed Consolidated Statements of Income

|  | Three Months Ended |  | Nine Months Ended
(In thousands, except for per share data) |  | July 31, 2023 |  | July 31, 2022 |  | July 31, 2023 |  | July 31, 2022
Sales |  | $ | 648,677 |  |  | $ | 662,128 |  |  | $ | 1,909,319 |  |  | $ | 1,906,697 |
Operating costs and expenses: |  |  |  |  |  |  |  |
Cost of sales |  | 288,357 |  |  | 296,544 |  |  | 868,007 |  |  | 843,344 |
Selling and administrative expenses |  | 189,324 |  |  | 180,666 |  |  | 553,590 |  |  | 538,602 |
|  | 477,681 |  |  | 477,210 |  |  | 1,421,597 |  |  | 1,381,946 |
Operating profit |  | 170,996 |  |  | 184,918 |  |  | 487,722 |  |  | 524,751 |
Other income (expense): |  |  |  |  |  |  |  |
Interest expense |  | (12,089) |  |  | (5,737) |  |  | (32,532) |  |  | (16,748) |
Interest and investment income |  | 603 |  |  | 572 |  |  | 1,628 |  |  | 1,456 |
Other income (expense)- net |  | 2,542 |  |  | 752 |  |  | (2,059) |  |  | (37,720) |
|  | (8,944) |  |  | (4,413) |  |  | (32,963) |  |  | (53,012) |
Income before income taxes |  | 162,052 |  |  | 180,505 |  |  | 454,759 |  |  | 471,739 |
Income taxes |  | 34,161 |  |  | 38,694 |  |  | 95,044 |  |  | 99,885 |
Net income |  | $ | 127,891 |  |  | $ | 141,811 |  |  | $ | 359,715 |  |  | $ | 371,854 |
Average common shares |  | 56,989 |  |  | 57,409 |  |  | 57,114 |  |  | 57,782 |
Incremental common shares attributable to equity compensation |  | 541 |  |  | 560 |  |  | 543 |  |  | 610 |
Average common shares and common share equivalents |  | 57,530 |  |  | 57,969 |  |  | 57,657 |  |  | 58,392 |
Basic earnings per share |  | $ | 2.24 |  |  | $ | 2.47 |  |  | $ | 6.30 |  |  | $ | 6.44 |
Diluted earnings per share |  | $ | 2.22 |  |  | $ | 2.45 |  |  | $ | 6.24 |  |  | $ | 6.37 |

See accompanying notes.
Page 3

Table of Contents
Nordson Corporation
Consolidated Statements of Comprehensive Income

|  | Three Months Ended |  | Nine Months Ended
(In thousands) |  | July 31, 2023 |  | July 31, 2022 |  | July 31, 2023 |  | July 31, 2022
Net income |  | $ | 127,891 |  |  | $ | 141,811 |  |  | $ | 359,715 |  |  | $ | 371,854 |
Components of other comprehensive income (loss): |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | 3,455 |  |  | (21,220) |  |  | 79,986 |  |  | (81,479) |
Pension settlement adjustment, net of tax |  | — |  |  | — |  |  | — |  |  | 32,047 |
Pension and other postretirement plan adjustments, net of tax |  | (159) |  |  | 1,848 |  |  | (908) |  |  | 7,686 |
Total other comprehensive income (loss) |  | 3,296 |  |  | (19,372) |  |  | 79,078 |  |  | (41,746) |
Total comprehensive income |  | $ | 131,187 |  |  | $ | 122,439 |  |  | $ | 438,793 |  |  | $ | 330,108 |

See accompanying notes.
Page 4

Table of Contents
Nordson Corporation
Consolidated Balance Sheets

(In thousands) |  |  |  |
Assets |  |  |  |
Current assets: |  | July 31, 2023 |  | October 31, 2022
Cash and cash equivalents |  | $ | 143,138 |  |  | $ | 163,457 |
Receivables - net |  | 533,793 |  |  | 537,313 |
Inventories - net |  | 439,741 |  |  | 383,398 |
Prepaid expenses and other current assets |  | 60,249 |  |  | 48,803 |
Total current assets |  | 1,176,921 |  |  | 1,132,971 |
Goodwill |  | 2,110,780 |  |  | 1,804,693 |
Intangible assets - net |  | 350,524 |  |  | 329,402 |
Property, plant and equipment - net |  | 350,735 |  |  | 353,442 |
Operating right of use lease assets |  | 104,592 |  |  | 102,279 |
Deferred income taxes |  | 12,199 |  |  | 10,447 |
Other assets |  | 91,281 |  |  | 87,141 |
Total assets |  | $ | 4,197,032 |  |  | $ | 3,820,375 |
Liabilities and shareholders' equity |  |  |  |
Current liabilities: |  |  |  |
Current maturities of long-term debt and notes payable |  | $ | 110,643 |  |  | $ | 392,537 |
Accrued liabilities |  | 169,635 |  |  | 206,828 |
Accounts payable |  | 105,075 |  |  | 99,276 |
Customer advanced payments |  | 95,274 |  |  | 92,584 |
Income taxes payable |  | 26,661 |  |  | 22,333 |
Operating lease liability - current |  | 16,809 |  |  | 15,738 |
Finance lease liability - current |  | 4,512 |  |  | 4,907 |
Total current liabilities |  | 528,609 |  |  | 834,203 |
Long-term debt |  | 727,455 |  |  | 345,320 |
Operating lease liability - noncurrent |  | 91,287 |  |  | 90,768 |
Deferred income taxes |  | 119,734 |  |  | 110,781 |
Postretirement obligations |  | 57,528 |  |  | 56,804 |
Pension obligations |  | 46,782 |  |  | 40,551 |
Finance lease liability - noncurrent |  | 10,507 |  |  | 11,184 |
Other long-term liabilities |  | 35,324 |  |  | 36,389 |
Shareholders' equity: |  |  |  |
Common shares |  | 12,253 |  |  | 12,253 |
Capital in excess of stated value |  | 660,218 |  |  | 626,697 |
Retained earnings |  | 3,900,384 |  |  | 3,652,216 |
Accumulated other comprehensive loss |  | (128,704) |  |  | (207,782) |
Common shares in treasury, at cost |  | (1,864,345) |  |  | (1,789,009) |
Total shareholders' equity |  | 2,579,806 |  |  | 2,294,375 |
Total liabilities and shareholders' equity |  | $ | 4,197,032 |  |  | $ | 3,820,375 |

See accompanying notes.
Page 5

Table of Contents
Nordson Corporation
Consolidated Statements of Shareholders’ Equity

|  | Nine Months Ended July 31, 2023
(In thousands, except for share and per share data) |  | Common Shares |  | Additional Paid-in Capital |  | Retained Earnings |  | Accumulated Other Comprehensive Income (Loss) |  | Common Shares in Treasury, at cost |  | TOTAL
November 1, 2022 |  | $ | 12,253 |  |  | $ | 626,697 |  |  | $ | 3,652,216 |  |  | $ | (207,782) |  |  | $ | (1,789,009) |  |  | $ | 2,294,375 |
Shares issued under company stock and employee benefit plans |  | — |  |  | 7,032 |  |  | — |  |  | — |  |  | 1,775 |  |  | 8,807 |
Stock-based compensation |  | — |  |  | 7,071 |  |  | — |  |  | — |  |  | — |  |  | 7,071 |
Purchase of treasury shares |  | — |  |  | — |  |  | — |  |  | — |  |  | (6,875) |  |  | (6,875) |
Dividends declared ($0.65 per share) |  | — |  |  | — |  |  | (37,199) |  |  | — |  |  | — |  |  | (37,199) |
Net income |  | — |  |  | — |  |  | 104,261 |  |  | — |  |  | — |  |  | 104,261 |
Other Comprehensive Income (Loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | — |  |  | — |  |  | — |  |  | 76,821 |  |  | — |  |  | 76,821 |
Defined benefit pension and post-retirement plan adjustments |  | — |  |  | — |  |  | — |  |  | (576) |  |  | — |  |  | (576) |
January 31, 2023 |  | $ | 12,253 |  |  | $ | 640,800 |  |  | $ | 3,719,278 |  |  | $ | (131,537) |  |  | $ | (1,794,109) |  |  | $ | 2,446,685 |
Shares issued under company stock and employee benefit plans |  | — |  |  | 2,632 |  |  | — |  |  | — |  |  | 369 |  |  | 3,001 |
Stock-based compensation |  | — |  |  | 4,970 |  |  | — |  |  | — |  |  | — |  |  | 4,970 |
Purchase of treasury shares |  | — |  |  | — |  |  | — |  |  | — |  |  | (47,490) |  |  | (47,490) |
Dividends declared ($0.65 per share) |  | — |  |  | — |  |  | (37,264) |  |  | — |  |  | — |  |  | (37,264) |
Net income |  | — |  |  | — |  |  | 127,563 |  |  | — |  |  | — |  |  | 127,563 |
Other Comprehensive Income (Loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | — |  |  | — |  |  | — |  |  | (290) |  |  | — |  |  | (290) |
Defined benefit pension and post-retirement plan adjustments |  | — |  |  | — |  |  | — |  |  | (173) |  |  | — |  |  | (173) |
April 30, 2023 |  | $ | 12,253 |  |  | $ | 648,402 |  |  | $ | 3,809,577 |  |  | $ | (132,000) |  |  | $ | (1,841,230) |  |  | $ | 2,497,002 |
Shares issued under company stock and employee benefit plans |  | — |  |  | 5,958 |  |  | — |  |  | — |  |  | 683 |  |  | 6,641 |
Stock-based compensation |  | — |  |  | 5,858 |  |  | — |  |  | — |  |  | — |  |  | 5,858 |
Purchase of treasury shares |  | — |  |  | — |  |  | — |  |  | — |  |  | (23,798) |  |  | (23,798) |
Dividends declared ($0.65 per share) |  | — |  |  | — |  |  | (37,084) |  |  | — |  |  | — |  |  | (37,084) |
Net income |  | — |  |  | — |  |  | 127,891 |  |  | — |  |  | — |  |  | 127,891 |
Other Comprehensive Income (Loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | — |  |  | — |  |  | — |  |  | 3,455 |  |  | — |  |  | 3,455 |
Defined benefit pension and post-retirement plan adjustments |  | — |  |  | — |  |  | — |  |  | (159) |  |  | — |  |  | (159) |
July 31, 2023 |  | $ | 12,253 |  |  | $ | 660,218 |  |  | $ | 3,900,384 |  |  | $ | (128,704) |  |  | $ | (1,864,345) |  |  | $ | 2,579,806 |

Page 6

Table of Contents
Nordson Corporation
Consolidated Statements of Shareholders’ Equity

|  | Nine Months Ended July 31, 2022
(In thousands, except for share and per share data) |  | Common Shares |  | Additional Paid-in Capital |  | Retained Earnings |  | Accumulated Other Comprehensive Income (Loss) |  | Common Shares in Treasury, at cost |  | TOTAL
November 1, 2021 |  | $ | 12,253 |  |  | $ | 585,334 |  |  | $ | 3,265,027 |  |  | $ | (175,835) |  |  | $ | (1,527,649) |  |  | $ | 2,159,130 |
Shares issued under company stock and employee benefit plans |  | — |  |  | 5,046 |  |  | — |  |  | — |  |  | 675 |  |  | 5,721 |
Stock-based compensation |  | — |  |  | 8,392 |  |  | — |  |  | — |  |  | — |  |  | 8,392 |
Purchase of treasury shares |  | — |  |  | — |  |  | — |  |  | — |  |  | (35,002) |  |  | (35,002) |
Dividends declared ($0.51 per share) |  | — |  |  | — |  |  | (29,724) |  |  | — |  |  | — |  |  | (29,724) |
Net income |  | — |  |  | — |  |  | 120,409 |  |  | — |  |  | — |  |  | 120,409 |
Other Comprehensive Income (Loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | — |  |  | — |  |  | — |  |  | (13,358) |  |  | — |  |  | (13,358) |
Defined benefit pension and post-retirement plan adjustments |  | — |  |  | — |  |  | — |  |  | 3,060 |  |  | — |  |  | 3,060 |
January 31, 2022 |  | $ | 12,253 |  |  | $ | 598,772 |  |  | $ | 3,355,712 |  |  | $ | (186,133) |  |  | $ | (1,561,976) |  |  | $ | 2,218,628 |
Shares issued under company stock and employee benefit plans |  | — |  |  | 1,843 |  |  | — |  |  | — |  |  | 234 |  |  | 2,077 |
Stock-based compensation |  | — |  |  | 7,394 |  |  | — |  |  | — |  |  | — |  |  | 7,394 |
Purchase of treasury shares |  | — |  |  | — |  |  | — |  |  | — |  |  | (105,464) |  |  | (105,464) |
Dividends declared ($0.51 per share) |  | — |  |  | — |  |  | (29,577) |  |  | — |  |  | — |  |  | (29,577) |
Net income |  | — |  |  | — |  |  | 109,634 |  |  | — |  |  | — |  |  | 109,634 |
Other Comprehensive Income (Loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | — |  |  | — |  |  | — |  |  | (46,901) |  |  | — |  |  | (46,901) |
Pension plan settlement adjustment |  | — |  |  | — |  |  | — |  |  | 32,047 |  |  | — |  |  | 32,047 |
Defined benefit pension and post-retirement plan adjustments |  | — |  |  | — |  |  | — |  |  | 2,778 |  |  | — |  |  | 2,778 |
April 30, 2022 |  | $ | 12,253 |  |  | $ | 608,009 |  |  | $ | 3,435,769 |  |  | $ | (198,209) |  |  | $ | (1,667,206) |  |  | $ | 2,190,616 |
Shares issued under company stock and employee benefit plans |  | — |  |  | 940 |  |  | — |  |  | — |  |  | 107 |  |  | 1,047 |
Stock-based compensation |  | — |  |  | 7,618 |  |  | — |  |  | — |  |  | — |  |  | 7,618 |
Purchase of treasury shares |  | — |  |  | — |  |  | — |  |  | — |  |  | (93,301) |  |  | (93,301) |
Dividends declared ($0.51 per share) |  | — |  |  | — |  |  | (29,374) |  |  | — |  |  | — |  |  | (29,374) |
Net income |  | — |  |  | — |  |  | 141,811 |  |  | — |  |  | — |  |  | 141,811 |
Other Comprehensive Income (Loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | — |  |  | — |  |  | — |  |  | (21,220) |  |  | — |  |  | (21,220) |
Defined benefit pension and post-retirement plan adjustments |  | — |  |  | — |  |  | — |  |  | 1,848 |  |  | — |  |  | 1,848 |
July 31, 2022 |  | $ | 12,253 |  |  | $ | 616,567 |  |  | $ | 3,548,206 |  |  | $ | (217,581) |  |  | $ | (1,760,400) |  |  | $ | 2,199,045 |

See accompanying notes.
Page 7

Table of Contents
Nordson Corporation
Condensed Consolidated Statements of Cash Flows

(In thousands) |  | Nine Months Ended
Cash flows from operating activities: |  | July 31, 2023 |  | July 31, 2022
Net income |  | $ | 359,715 |  |  | $ | 371,854 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |
Depreciation and amortization |  | 80,637 |  |  | 75,242 |
Non-cash stock compensation |  | 17,067 |  |  | 23,404 |
Deferred income taxes |  | (930) |  |  | (11,094) |
Other non-cash expense |  | 762 |  |  | 43,325 |
Loss on sale of property, plant and equipment |  | 1,624 |  |  | (707) |
Changes in operating assets and liabilities |  | 19,197 |  |  | (162,333) |
Net cash provided by operating activities |  | 478,072 |  |  | 339,691 |
Cash flows from investing activities: |  |  |  |
Additions to property, plant and equipment |  | (24,244) |  |  | (39,373) |
Proceeds from sale of property, plant and equipment |  | 91 |  |  | 415 |
Acquisition of business, net of cash acquired |  | (377,843) |  |  | (171,613) |
Net cash used in investing activities |  | (401,996) |  |  | (210,571) |
Cash flows from financing activities: |  |  |  |
Proceeds from long-term debt |  | 1,279,151 |  |  | 63,067 |
Repayment of long-term debt |  | (1,205,195) |  |  | (40,162) |
Repayment of finance lease obligations |  | (4,769) |  |  | (3,726) |
Issuance of common shares |  | 18,449 |  |  | 8,845 |
Purchase of treasury shares |  | (78,163) |  |  | (233,767) |
Dividends paid |  | (111,547) |  |  | (88,675) |
Net cash used in financing activities |  | (102,074) |  |  | (294,418) |
Effect of exchange rate changes on cash |  | 5,679 |  |  | (5,937) |
Decrease in cash and cash equivalents |  | (20,319) |  |  | (171,235) |
Cash and cash equivalents at beginning of period |  | 163,457 |  |  | 299,972 |
Cash and cash equivalents at end of period |  | $ | 143,138 |  |  | $ | 128,737 |

See accompanying notes.
Page 8

Table of Contents
Nordson Corporation
Notes to Condensed Consolidated Financial Statements
July 31, 2023
NOTE REGARDING AMOUNTS AND FISCAL YEAR REFERENCES
In this quarterly report, all amounts related to United States dollars and foreign currency and to the number of Nordson Corporation’s common shares, except for per share earnings and dividend amounts, are expressed in thousands. Unless the context otherwise indicates, all references to “we” or the “Company” mean Nordson Corporation.
Unless otherwise noted, all references to years relate to our fiscal year ending October 31.
Significant accounting policies
Basis of presentation. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles in the United States (U.S. GAAP) for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended July 31, 2023 are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the Consolidated Financial Statements and notes included in our Annual Report on Form 10-K for the year ended October 31, 2022.
Consolidation. The Condensed Consolidated Financial Statements include the accounts of Nordson Corporation and its 100%-owned and controlled subsidiaries. Investments in affiliates and joint ventures in which our ownership is 50% or less or in which we do not have control but have the ability to exercise significant influence, are accounted for under the equity method. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of estimates. The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements. Actual amounts could differ from these estimates.
Revenue recognition. A contract exists when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied. Generally, our revenue results from short-term, fixed-price contracts and primarily is recognized as of a point in time when the product is shipped or at a later point when the control of the product transfers to the customer. Revenue for undelivered items is deferred and included within Accrued liabilities in our Consolidated Balance Sheets. Revenues deferred as of July 31, 2023 and 2022 were not material.
However, for certain contracts related to the sale of customer-specific products within our Medical and Fluid Solutions segment, revenue is recognized over time as we satisfy performance obligations because of the continuous transfer of control to the customer. The continuous transfer of control to the customer occurs as we enhance assets that are customer controlled and we are contractually entitled to payment for work performed to date plus a reasonable margin.
As control transfers over time, revenue is recognized based on progress toward completion of the performance obligations. The selection method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. We have elected to use the input method – costs incurred for these contracts because it best depicts the transfer of products or services to the customer based on incurring costs on the contract. Under this method, revenues are recorded proportionally as costs are incurred. Contract assets recognized are recorded in Prepaid expenses and other current assets and contract liabilities are recorded in Accrued liabilities in our Consolidated Balance Sheets and were not material on July 31, 2023 and October 31, 2022. Revenue recognized over time represented approximately less than ten percent of our overall consolidated revenues at July 31, 2023 and October 31, 2022.
Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services. Taxes, including sales and value add, that we collect concurrently with revenue-producing activities are excluded from revenue. As a practical expedient, we may exclude the assessment of whether goods or services are performance obligations, if they are immaterial in the context of the contract, and combine these with other performance obligations. While payment terms and conditions vary by contract type, we have determined that our contracts generally do not include a significant financing component. We have elected to apply the practical expedient to treat all shipping and handling costs as fulfillment costs as a significant portion of these costs are incurred prior to transfer of control to the customer. We have also elected to apply the practical expedient to expense sales commissions as they are incurred as the amortization period resulting from capitalizing the
Page 9

Table of Contents
Nordson Corporation
costs is one year or less. These costs are recorded within Selling and administrative expenses in our Condensed Consolidated Statements of Income.
We offer assurance-type warranties on our products as well as separately sold warranty contracts. Revenue related to warranty contracts that are sold separately is recognized over the life of the warranty term and are not material. Certain arrangements may include installation, installation supervision, training, and spare parts, which tend to be completed in a short period of time, at an insignificant cost, and utilizing skills not unique to us, and, therefore, these items are typically regarded as inconsequential or not material.
We disclose disaggregated revenues by operating segment and geography in accordance with the revenue standard and on the same basis used internally by the chief operating decision maker for evaluating performance of operating segments and for allocating resources. Refer to our Operating segments Note for details.
Earnings per share. Basic earnings per share are computed based on the weighted-average number of common shares outstanding during each year, while diluted earnings per share are based on the weighted-average number of common shares and common share equivalents outstanding. Common share equivalents consist of shares issuable upon exercise of stock options computed using the treasury stock method, as well as restricted shares and deferred stock-based compensation. Options whose exercise price is higher than the average market price are excluded from the calculation of diluted earnings per share because the effect would be anti-dilutive. Options excluded from the calculation of diluted earnings per share for the three months ended July 31, 2023 and 2022 were 138 and 76, respectively. Options excluded from the calculation of diluted earnings per share for the nine months ended July 31, 2023 and 2022 were 141 and 79, respectively.
Recently issued accounting standards
There have been no new accounting standards issued which would require either disclosure or adoption during the current periods.
Acquisitions
Business acquisitions have been accounted for using the acquisition method, with the acquired assets and liabilities recorded at estimated fair value on the dates of acquisition. The cost in excess of the net assets of the business acquired is included in goodwill. Operating results since the respective dates of acquisitions are included in the Condensed Consolidated Statements of Income.
2023 Acquisitions
On August 24, 2023, the Company completed the acquisition of the ARAG Group and its subsidiaries (ARAG Group or ARAG) pursuant to the terms of the Sale and Purchase Agreement, dated as of June 25, 2023, by and among the Company, its Italian subsidiary, Capvis Equity V LP (Capvis), DRIP Co-Investment (DRIP), and certain individuals (the Individual Sellers, and together with Capvis and DRIP, collectively, the Sellers). ARAG is a global market and innovation leader in the development, production and supply of precision control systems and smart fluid components for agricultural spraying. ARAG will operate as a division of our Industrial Precision Solutions segment. In anticipation of the acquisition, the Company entered into a €760,000 senior unsecured term loan facility with a group of banks in August 2023 (the Term F acility). The Term Facility has a 364-day term and matures in August 2024, and loans under the facility bear interest at a eurocurrency rate plus an applicable margin that will range from 1.1250% to 1.625% based on the Company’s Leverage Ratio (as defined in the term loan credit agreement and calculated on a consolidated net debt basis). The all-cash ARAG acquisition of approximately €957,000, net of the repayment of approximately €30,300 of debt of the acquired companies, was funded using the Term Facility and Revolving Facility. The financial results of the ARAG Group acquisition are not expected to have a material impact on our Consolidated Financial Statements.
On November 3, 2022, we acquired 100% of CyberOptics Corporation (CyberOptics). CyberOptics is a leading global developer and manufacturer of high-precision 3D optical sensing technology solutions. The CyberOptics acquisition expanded our test and inspection platform, providing differentiated technology that expands our product offering in the semiconductor and electronics industries and is reported in our Advanced Technology Solutions segment. We acquired CyberOptics for an aggregate purchase price of $377,843, net of cash of approximately $40,890, funded using borrowings under our revolving credit facility and cash on hand. Based on the fair value of the assets acquired and the liabilities assumed, goodwill of $279,630 and identifiable intangible assets of $58,600 were recorded. The identifiable intangible assets consist primarily of $15,200 of tradenames (amortized over fifteen years), $14,600 of technology (amortized over seven years), and $28,800 of customer contracts (amortized over twelve years). T he results of CyberOptics are not material to our Consolidated Financial Statements. As of July 31, 2023, t he purchase price allocation remains preliminary as we complete our assessment of intangibles and income taxes.
Page 10

Table of Contents
Nordson Corporation
The assets and liabilities acquired were as follows:

| November 3, 2022 |  |
Cash | $ | 40,890 |  |  |
Receivables - net | 21,364 |  |  |
Inventories - net | 35,300 |  |  |
Goodwill | 279,630 |  |  |
Intangibles | 58,600 |  |  |
Other assets | 14,046 |  |  |
Total Assets | $ | 449,830 |  |  |
Accounts payable | $ | 8,109 |  |  |
Deferred income taxes | 14,294 |  |  |
Other liabilities | 8,694 |  |  |
Total Liabilities | $ | 31,097 |  |  |

2022 Acquisition
On November 1, 2021, we acquired 100% of NDC Technologies (NDC), a leading global provider of precision measurement solutions for in-line manufacturing process control. NDC's technology portfolio includes in-line measurement sensors, gauges and analyzers using near-infrared, laser, X-ray, optical and nucleonic technologies, as well as proprietary algorithms and software. We acquired NDC for an aggregate purchase price of $171,613, net of cash of approximately $7,533 and other working capital adjustments of $2,763, utilizing cash on hand. Based on the fair value of the assets acquired and the liabilities assumed, goodwill of $131,129 and identifiable intangible assets of $31,130 were recorded. The identifiable intangible assets consist primarily of $10,800 of tradenames (amortized over thirteen years), $10,000 of technology (amortized over seven years), $9,500 of customer relationships (amortized over four years) and $830 of non-compete agreements (amortized over three years). Goodwill associated with this acquisition of $72,018 is tax deductible. This acquisition is being reported in our Industrial Precision Solutions segment and the results of NDC are not material to our Consolidated Financial Statements.
Receivables
Our allowance for credit losses is principally determined based on aging of receivables. Receivables are exposed to credit risk based on the customers' ability to pay which is influenced by, among other factors, their financial liquidity. We perform ongoing customer credit evaluation to maintain sufficient allowances for potential credit losses. Our segments perform credit evaluation and monitoring to estimate and manage credit risk through the review of customer information, credit ratings, approval and monitoring of customer credit limits, and assessment of market conditions. We may also require prepayments or bank guarantees from customers to mitigate credit risk. Our receivables are generally short-term in nature with a majority of receivables outstanding less than 90 days. Accounts receivable balances are written-off against the allowance if deemed uncollectible.
Accounts receivable are net of an allowance for credit losses of $8,076 and $8,218 on July 31, 2023 and October 31, 2022, respectively. Provision losses related to allowance for credit losses of $410 and provision income of $239 was recorded for the three and nine months ended July 31, 2023, respectively, compared to provision expense of $788 and $1,439 for the same periods a year ago, respectively. The remaining change in the allowance for credit losses is principally related to net write-off/recoveries of uncollectible accounts as well as currency translation.
Inventories
Components of inventories were as follows:

|  | July 31, 2023 |  | October 31, 2022
Finished goods |  | $ | 234,690 |  |  | $ | 218,491 |
Raw materials and component parts |  | 200,475 |  |  | 157,447 |
Work-in-process |  | 62,856 |  |  | 53,195 |
|  | 498,021 |  |  | 429,133 |
Obsolescence and other reserves |  | (58,280) |  |  | (45,735) |
|  | $ | 439,741 |  |  | $ | 383,398 |

See Acquisitions Note for inventory increase attributable to acquisition of CyberOptics.
Page 11

Table of Contents
Nordson Corporation
Property, Plant and Equipment
Components of property, plant and equipment were as follows:

| July 31, 2023 |  | October 31, 2022
Land | $ | 9,856 |  |  | $ | 9,278 |
Land improvements | 5,033 |  |  | 4,979 |
Buildings | 282,260 |  |  | 271,450 |
Machinery and equipment | 536,215 |  |  | 505,343 |
Enterprise management system | 52,938 |  |  | 52,513 |
Construction-in-progress | 20,130 |  |  | 31,466 |
Leased property under finance leases | 28,047 |  |  | 27,512 |
| 934,479 |  |  | 902,541 |
Accumulated depreciation and amortization | (583,744) |  |  | (549,099) |
| $ | 350,735 |  |  | $ | 353,442 |

Depreciation expense was $13,180 and $12,178 for the three months ended July 31, 2023 and 2022, respectively. Depreciation expense was $38,798 and $36,876 for the nine months ended July 31, 2023 and 2022, respectively.
Goodwill and other intangible assets
Changes in the carrying amount of goodwill for th e nine months ended July 31, 2023 by operating segment were as follows:

|  | Industrial Precision Solutions |  | Medical Fluid Systems |  | Advanced Technology Solutions |  | Total
Balance at October 31, 2022 |  | $ | 520,236 |  |  | $ | 1,172,069 |  |  | $ | 112,388 |  |  | $ | 1,804,693 |
Acquisitions |  | — |  |  | — |  |  | 279,630 |  |  | 279,630 |
Currency effect |  | 4,744 |  |  | 3,869 |  |  | 17,844 |  |  | 26,457 |
Balance at July 31, 2023 |  | $ | 524,980 |  |  | $ | 1,175,938 |  |  | $ | 409,862 |  |  | $ | 2,110,780 |

The increase in goodwill for the nine months ended July 31, 2023 was due to the acquisition of CyberOptics. See Acquisitions Note for additional details.
Page 12

Table of Contents
Nordson Corporation
Information regarding our intangible assets subject to amortization was as follows:

|  | July 31, 2023
|  | Carrying Amount |  | Accumulated Amortization |  | Net Book Value
Customer relationships |  | $ | 517,147 |  |  | $ | 282,598 |  |  | $ | 234,549 |
Patent/technology costs |  | 176,396 |  |  | 109,783 |  |  | 66,613 |
Trade name |  | 99,413 |  |  | 50,673 |  |  | 48,740 |
Non-compete agreements |  | 10,559 |  |  | 9,937 |  |  | 622 |
Other |  | 143 |  |  | 143 |  |  | — |
Total |  | $ | 803,658 |  |  | $ | 453,134 |  |  | $ | 350,524 |
|  | October 31, 2022
|  | Carrying Amount |  | Accumulated Amortization |  | Net Book Value
Customer relationships |  | $ | 480,058 |  |  | $ | 250,798 |  |  | $ | 229,260 |
Patent/technology costs |  | 157,549 |  |  | 96,426 |  |  | 61,123 |
Trade name |  | 82,759 |  |  | 44,707 |  |  | 38,052 |
Non-compete agreements |  | 10,253 |  |  | 9,290 |  |  | 963 |
Other |  | 446 |  |  | 442 |  |  | 4 |
Total |  | $ | 731,065 |  |  | $ | 401,663 |  |  | $ | 329,402 |

Amortization expense for the three months ended July 31, 2023 and 2022 was $13,922 and $12,709, respectively. Amortization expense for the nine months ended July 31, 2023 and 2022 was $41,839 and $38,366, respectively. See Acquisitions Note for details regarding intangibles recorded due to the acquisition of CyberOptics.
Pension and other postretirement plans
During the second quarter of 2022, we completed a partial plan settlement transaction in regards to two of our U.S. pension plans in which plan assets amounting to $171,181 were used to purchase a group annuity contract from The Prudential Insurance Company of America (Prudential). The settlement resulted in a loss of $41,221, which is included in Other-net on the Condensed Consolidated Statements of Income. This transaction relieved the Company of its responsibility for the pension obligation related to certain retired employees and transferred the obligation and payment responsibility to Prudential for retirement benefits owed to approximately 1,500 retirees and other beneficiaries. The annuity contract covered retirees who commenced receiving benefits on or before November 1, 2021. The monthly retirement benefit payment amounts currently received by retirees and their beneficiaries did not change as a result of this transaction. Plan participants not included in the transaction remain in the plans and responsibility for payment of the retirement benefits remains with the Company.
Page 13

Table of Contents
Nordson Corporation
The components of net periodic pension and other postretirement cost for the three and nine months ended July 31, 2023 and 2022 were:

|  | U.S. |  | International
Three Months Ended |  | 2023 |  | 2022 |  | 2023 |  | 2022
Service cost |  | $ | 2,744 |  |  | $ | 3,423 |  |  | $ | 281 |  |  | $ | 423 |
Interest cost |  | 4,176 |  |  | 3,322 |  |  | 642 |  |  | 272 |
Expected return on plan assets |  | (6,529) |  |  | (5,692) |  |  | (392) |  |  | (347) |
Amortization of prior service cost (credit) |  | — |  |  | 12 |  |  | (13) |  |  | (13) |
Amortization of net actuarial loss |  | — |  |  | 1,197 |  |  | 20 |  |  | 558 |
Total benefit cost |  | $ | 391 |  |  | $ | 2,262 |  |  | $ | 538 |  |  | $ | 893 |
|  | U.S. |  | International
Nine Months Ended |  | 2023 |  | 2022 |  | 2023 |  | 2022
Service cost |  | $ | 8,233 |  |  | $ | 13,338 |  |  | $ | 838 |  |  | $ | 1,343 |
Interest cost |  | 12,526 |  |  | 11,146 |  |  | 1,887 |  |  | 861 |
Expected return on plan assets |  | (19,587) |  |  | (22,082) |  |  | (1,151) |  |  | (1,109) |
Amortization of prior service cost (credit) |  | — |  |  | 36 |  |  | (38) |  |  | (43) |
Amortization of net actuarial loss |  | — |  |  | 6,282 |  |  | 61 |  |  | 1,758 |
Settlement loss |  | — |  |  | 41,221 |  |  | — |  |  | — |
Total benefit cost |  | $ | 1,172 |  |  | $ | 49,941 |  |  | $ | 1,597 |  |  | $ | 2,810 |

The components of other postretirement benefit costs for the three and nine months ended July 31, 2023 and 2022 were:

|  | U.S. |  | International
Three Months Ended |  | 2023 |  | 2022 |  | 2023 |  | 2022
Service cost |  | $ | 100 |  |  | $ | 172 |  |  | $ | 1 |  |  | $ | 3 |
Interest cost |  | 766 |  |  | 481 |  |  | 3 |  |  | 3 |
Amortization of net actuarial (gain) loss |  | — |  |  | 244 |  |  | (16) |  |  | (12) |
Total benefit cost (income) |  | $ | 866 |  |  | $ | 897 |  |  | $ | (12) |  |  | $ | (6) |
|  | U.S. |  | International
Nine Months Ended |  | 2023 |  | 2022 |  | 2023 |  | 2022
Service cost |  | $ | 299 |  |  | $ | 515 |  |  | $ | 4 |  |  | $ | 9 |
Interest cost |  | 2,297 |  |  | 1,443 |  |  | 8 |  |  | 10 |
Amortization of net actuarial (gain) loss |  | — |  |  | 733 |  |  | (47) |  |  | (37) |
Total benefit cost (income) |  | $ | 2,596 |  |  | $ | 2,691 |  |  | $ | (35) |  |  | $ | (18) |

The components of net periodic pension and other postretirement cost other than service cost are included in Other – net in our Condensed Consolidated Statements of Income.
Income taxes
We record our interim provision for income taxes based on our estimated annual effective tax rate, as well as certain items discrete to the current periods. The effective tax rate for the three months ended July 31, 2023 and 2022 was 21.1% and 21.4%, respectively. The effective tax rate for the nine months ended July 31, 2023 and 2022 was 20.9% and 21.2%, respectively.
Due to our share-based payment transactions, our income tax provision included a discrete tax benefit of $996 and $2,745 for the three months and nine months ended July 31, 2023, respectively, compared to $115 and $1,539 for the three and nine months ended July 31, 2022, respectively.
Page 14

Table of Contents
Nordson Corporation
Accumulated other comprehensive income (loss)
The components of accumulated other comprehensive income (loss), including adjustments for items that are reclassified from accumulated other comprehensive loss to net income, are shown below.

|  | Cumulative translation adjustments |  | Pension and postretirement benefit plan adjustments |  | Accumulated other comprehensive income (loss)
Balance at October 31, 2022 |  | $ | (160,046) |  |  | $ | (47,736) |  |  | $ | (207,782) |
Pension and other postretirement plan adjustments, net of tax of ($305) |  | — |  |  | (908) |  |  | (908) |
Foreign currency translation adjustments (a) |  | 79,986 |  |  | — |  |  | 79,986 |
Balance at July 31, 2023 |  | $ | (80,060) |  |  | $ | (48,644) |  |  | $ | (128,704) |

(a) Includes a net loss of $3,672, net of tax of $1,097, on net investment hedges.
Stock-based compensation
During the 2021 Annual Meeting of Shareholders, our shareholders approved the Nordson Corporation 2021 Stock Incentive and Award Plan (the 2021 Plan) as the successor to the Amended and Restated 2012 Stock Incentive and Award Plan (the 2012 Plan). The 2021 Plan provides for the granting of stock options, stock appreciation rights, restricted shares, restricted share units, performance shares, cash awards and other stock or performance-based incentives. A maximum of 900 common shares were authorized for grant under the 2021 Plan plus the number of shares that remained available to be granted under the 2012 Plan, as well as issuable under the CyberOptics equity plan. As of July 31, 2023, a total of 2,012 common shares were available to be granted under the 2021 Plan.
Stock Options
Nonqualified or incentive stock options may be granted to our employees and directors. Generally, options granted to employees may be exercised beginning one year from the date of grant at a rate not exceeding 25% per year and expire 10 years from the date of grant. Vesting accelerates upon a qualified termination in connection with a change in control. In the event of termination of employment due to early retirement or normal retirement at age 65, options granted within 12 months prior to termination are forfeited, and vesting continues post retirement for all other unvested options granted. In the event of disability or death, all unvested stock options granted within 12 months prior to termination fully vest. Termination for any other reason results in forfeiture of unvested options and vested options in certain circumstances. The amortized cost of options is accelerated if the retirement eligibility date occurs before the normal vesting date. Option exercises are satisfied through the issuance of treasury shares on a first-in, first-out basis. We recognized compensation expense related to stock options of $1,697 and $4,982 for the three month and nine months ended July 31, 2023, respectively, compared to $1,580 and $5,743 for the three and nine months ended July 31, 2022, respectively.
The following table summarizes activity related to stock options for the nine months ended July 31, 2023:

|  | Number of Options |  | Weighted- Average Exercise Price Per Share |  | Aggregate Intrinsic Value |  | Weighted Average Remaining Term
Outstanding at October 31, 2022 |  | 1,187 |  | $ | 141.82 |  |  |  |  |
Granted |  | 80 |  | 239.44 |  |  |  |  |
Exercised |  | (163) |  | 115.67 |  |  |  |  |
Forfeited or expired |  | (10) |  | 206.93 |  |  |  |  |
Outstanding at July 31, 2023 |  | 1,094 |  | $ | 151.09 |  |  | $ | 111,165 |  |  | 5.1 years
Expected to vest |  | 245 |  | $ | 214.42 |  |  | $ | 10,006 |  |  | 7.5 years
Exercisable at July 31, 2023 |  | 846 |  | $ | 132.58 |  |  | $ | 101,014 |  |  | 4.4 years

As of July 31, 2023, there was $7,013 of total unrecognized compensation cost related to unvested stock options. That cost is expected to be amortized over a weighted average period of approximately 1.7 years.
Page 15

Table of Contents
Nordson Corporation
The fair value of each option grant was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Nine Months Ended | July 31, 2023 |  | July 31, 2022
Expected volatility | 30.4% | - | 31.8% |  | 30.6% | - | 30.8%
Expected dividend yield | 1.12% | - | 1.27% |  | 0.76% | - | 0.76%
Risk-free interest rate | 3.79% | - | 4.21% |  | 1.36% | - | 1.47%
Expected life of the option (in years) | 5.0 | - | 6.2 |  | 5.3 | - | 6.2

The weighted-average expected volatility used to value the 2023 and 2022 options was 30.6% and 30.6%, respectively.
Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options. The risk-free interest rate was selected based upon yields of U.S. Treasury issues with a term equal to the expected life of the option being valued.
The weighted average grant date fair value of stock options granted during the nine months ended July 31, 2023 and 2022 was $77.99 and $79.03, respectively.
The total intrinsic value of options exercised during the three months ended July 31, 2023 and 2022 was $7,741 and $1,052, respectively. The total intrinsic value of options exercised during the nine months ended July 31, 2023 and 2022 was $19,873 and $10,418, respectively.
Cash received from the exercise of stock options for the nine months ended July 31, 2023 and 2022 was $18,449 and $8,845, respectively.
Restricted Shares and Restricted Share Units
We may grant restricted shares and/or restricted share units to our employees and directors. These shares or units may not be transferred for a designated period of time (generally one to three years) defined at the date of grant. We may also grant continuation awards in the form of restricted share units with cliff vesting and a performance measure that must be achieved for the restricted share units to vest.
For employee recipients, in the event of termination of employment due to early retirement, with the consent of the Company, restricted shares and units granted within 12 months prior to termination are forfeited, and other restricted shares and units vest on a pro-rata basis, subject to the consent of the Compensation Committee. In the event of termination of employment due to normal retirement at age 65, restricted shares and units granted within 12 months prior to termination are forfeited, and, for other restricted shares and units, the restriction period applicable to restricted shares will lapse and the shares will vest and be transferable and all unvested units will become vested in full, subject to the consent of the Compensation Committee. In the event of a recipient's disability or death, all restricted shares and units granted within 12 months prior to termination fully vest. Termination for any other reason prior to the lapse of any restrictions or vesting of units results in forfeiture of the shares or units.
For non-employee directors, all restrictions lapse in the event of disability or death of the non-employee director. Termination of service as a director for any other reason within one year of date of grant results in a pro-rata vesting of shares or units.
As shares or units are issued, deferred stock-based compensation equivalent to the fair value on the date of grant is expensed over the vesting period.
The following table summarizes activity related to restricted shares during the nine months ended July 31, 2023:

|  | Number of Shares |  | Weighted-Average Grant Date Fair Value
Restricted shares at October 31, 2022 |  | 6 |  |  | $ | 167.99 |
Vested |  | (6) |  |  | 167.99
Restricted shares at July 31, 2023 |  | — |  |  | $ | — |

As of July 31, 2023, there was no unrecognized compensation cost related to restricted shares. The amount charged to expense related to restricted shares during the three months ended July 31, 2023 and 2022 was $73 and $243, respectively, which included common share dividends of $2 and $4, respectively. For the nine months ended July 31, 2023 and 2022, the amounts charged to expense related to restricted shares were $336 and $856, respectively, which included common shares dividends of $5 and $14, respectively.
Page 16

Table of Contents
Nordson Corporation
The following table summarizes activity related to restricted share units during the nine months ended July 31, 2023:

|  | Number of Units |  | Weighted-Average Grant Date Fair Value
Restricted share units at October 31, 2022 |  | 81 |  |  | $ | 223.77 |
Granted |  | 39 |  |  | 237.18
Forfeited |  | (5) |  |  | 241.37
Vested |  | (45) |  |  | 219.06
Restricted share units at July 31, 2023 |  | 70 |  |  | $ | 232.88 |

As of July 31, 2023, there was $10,080 of remaining expense to be recognized related to outstanding restricted share units, which is expected to be recognized over a weighted average period of 1.8 years. The amount charged to expense related to restricted share units during each of the three months ended July 31, 2023 and 2022 was $2,152 and $2,154, respectively, compared to $6,658 and $6,246 for the nine months ended July 31, 2023 and 2022, respectively.
Performance Share Incentive Awards
Executive officers and selected other key employees are eligible to receive common share-based incentive awards. Payouts, in the form of unrestricted common shares, vary based on the degree to which corporate financial performance exceeds predetermined threshold, target and maximum performance goals over three-year performance periods. No payout will occur unless threshold performance is achieved.
The amount of compensation expense is based upon current performance projections and the percentage of the requisite service that has been rendered. The calculations are based upon the grant date fair value, which is principally driven by the stock price on the date of grant or a Monte Carlo valuation for awards with market conditions. The per share values were $231.34, $211.25 and $214.51 in 2023, and $260.60, $273.50 and $221.94 for 2022. The amount charged to expense related to performance awards for the three months ended July 31, 2023 and 2022 was $1,831 and $3,555, respectively, compared to charges of $4,785 and $10,296 for the nine months ended July 31, 2023 and 2022, respectively. As of July 31, 2023, there was $7,947 of unrecognized compensation cost related to performance share incentive awards.
Deferred Compensation
Our executive officers and other highly compensated employees may elect to defer up to 100% of their base pay and cash incentive compensation, and for executive officers, up to 90% of their share-based performance incentive payout each year. Additional share units are credited for quarterly dividends paid on our common shares. Expense related to dividends paid under this plan for the three months ended July 31, 2023 and 2022 was $30 and $17, respectively, compared to $77 and $53 for the nine months ended July 31, 2023 and 2022, respectively.
Deferred Directors' Compensation
Non-employee directors may defer all or part of their cash and equity-based compensation until retirement. Cash compensation may be deferred as cash or as share equivalent units. Deferred cash amounts are recorded as liabilities, and share equivalent units are recorded as equity. Additional share equivalent units are earned when common share dividends are declared.
The following table summarizes activity related to director deferred compensation share equivalent units during the nine months ended July 31, 2023:

|  | Number of Shares |  | Weighted-Average Grant Date Fair Value
Outstanding at October 31, 2022 |  | 90 |  |  | $ | 77.70 |
Distributions |  | (13) |  |  | 52.50
Outstanding at July 31, 2023 |  | 78 |  |  | $ | 84.02 |

The amount charged to expense related to director deferred compensation for the three months ended July 31, 2023 and 2022 was $76 and $73, respectively, compared to $234 and $224 for the nine months ended July 31, 2023 and 2022, respectively.
Page 17

Table of Contents
Nordson Corporation
Warranties
We offer warranties to our customers depending on the specific product and terms of the customer purchase agreement. A typical warranty program requires that we repair or replace defective products within a specified time period (generally one year) from the date of delivery or first use. We record an estimate for future warranty-related costs based on actual historical return rates. Based on analysis of return rates and other factors, the adequacy of our warranty provisions is adjusted as necessary. The liability for warranty costs is included in Accrued liabilities in the Consolidated Balance Sheets.
Following is a reconciliation of the product warranty liability for the nine months ended July 31, 2023 and 2022:

|  | July 31, 2023 |  | July 31, 2022
Beginning balance at October 31 |  | $ | 11,723 |  |  | $ | 11,113 |
Accruals for warranties |  | 14,938 |  |  | 12,496 |
Warranty payments |  | (12,939) |  |  | (10,704) |
Currency effect |  | 566 |  |  | (676) |
Ending balance |  | $ | 14,288 |  |  | $ | 12,229 |

Operating segments
We conduct business in three p rimary operating segments: Industrial Precision Solutions, Medical and Fluid Solutions, and Advanced Technology Solutions. The composition of segments and measure of segment profitability is consistent with that used by our chief operating decision maker. The primary measure used by the chief operating decision maker for purposes of making decisions about allocating resources to the segments and assessing performance is operating profit, which equals sales less cost of sales and certain operating expenses. Items below the operating profit line of the Condensed Consolidated Statements of Income (interest and investment income, interest expense and other income/expense) are excluded from the measure of segment profitability reviewed by our chief operating decision maker and are not presented by operating segment. The accounting policies of the segments are the same as those described in the Significant accounting policies Note.
Industrial Precision Solutions: This segment focuses on delivering proprietary dispensing and processing technology, both standard and highly customized equipment, to diverse end markets. Product lines commonly reduce material consumption, increase line efficiency through precision dispense and measurement and control, and enhance product brand and appearance. Components are used for dispensing adhesives, coatings, paint, finishes, sealants and other materials. This segment primarily serves the industrial, consumer durables and non-durables markets.
Medical and Fluid Solutions: This segment includes the Company’s fluid management solutions for medical, high-tech industrial and other diverse end markets. Related plastic tubing, balloons, catheters, syringes, cartridges, tips and fluid connection components are used to dispense or control fluids within customers’ medical devices or products, as well as production processes.
Advanced Technology Solutions: This segment focuses on products serving electronics end markets. Advanced Technology Solutions products integrate our proprietary product technologies found in progressive stages of an electronics customer’s production processes, such as surface treatment, precisely controlled dispensing of material and test and inspection to ensure quality and reliability. Applications include, but are not limited to, semiconductors, printed circuit boards, electronic components and automotive electronics.
Page 18

Table of Contents
Nordson Corporation
The following table presents information about our segments:

Three Months Ended |  | Industrial Precision Solutions |  | Medical and Fluid Solutions |  | Advanced Technology Solutions |  | Corporate |  | Total
July 31, 2023 |  |  |  |  |  |  |  |  |  |
Net external sales |  | $ | 338,257 |  |  | $ | 170,871 |  |  | $ | 139,549 |  |  | $ | — |  |  | $ | 648,677 |
Operating profit (loss) |  | 115,346 |  |  | 54,019 |  |  | 27,083 |  |  | (25,452) |  |  | 170,996 |
July 31, 2022 |  |  |  |  |  |  |  |  |  |
Net external sales |  | $ | 341,215 |  |  | $ | 177,840 |  |  | $ | 143,073 |  |  | $ | — |  |  | $ | 662,128 |
Operating profit (loss) |  | 119,706 |  |  | 58,103 |  |  | 28,155 |  |  | (21,046) |  |  | 184,918 |
Nine Months Ended |  |  |  |  |  |  |  |  |  |
July 31, 2023 |  |  |  |  |  |  |  |  |  |
Net external sales |  | $ | 985,610 |  |  | $ | 491,683 |  |  | $ | 432,026 |  |  | $ | — |  |  | $ | 1,909,319 |
Operating profit (loss) |  | 329,439 |  |  | 141,326 |  |  | 70,136 |  |  | (53,179) |  |  | 487,722 |
July 31, 2022 |  |  |  |  |  |  |  |  |  |
Net external sales |  | $ | 981,582 |  |  | $ | 508,836 |  |  | $ | 416,279 |  |  | $ | — |  |  | $ | 1,906,697 |
Operating profit (loss) |  | 324,089 |  |  | 165,510 |  |  | 95,533 |  |  | (60,381) |  |  | 524,751 |

We had significant sales in the following geographic regions:

|  | Three Months Ended |  | Nine Months Ended
|  | July 31, 2023 |  | July 31, 2022 |  | July 31, 2023 |  | July 31, 2022
Americas |  | $ | 290,515 |  |  | $ | 279,205 |  |  | $ | 834,125 |  |  | $ | 792,859 |
Europe |  | 167,536 |  |  | 151,659 |  |  | 498,379 |  |  | 479,900 |
Asia Pacific |  | 190,626 |  |  | 231,264 |  |  | 576,815 |  |  | 633,938 |
Total net external sales |  | $ | 648,677 |  |  | $ | 662,128 |  |  | $ | 1,909,319 |  |  | $ | 1,906,697 |

Fair value measurements
The inputs to the valuation techniques used to measure fair value are classified into the following categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs that are not corroborated by market data.
The following tables present the classification of our assets and liabilities measured at fair value on a recurring basis:

July 31, 2023 |  | Total |  | Level 1 |  | Level 2 |  | Level 3
Assets: |  |  |  |  |  |  |  |
Foreign currency forward contracts (a) |  | $ | 9,608 |  |  | $ | — |  |  | $ | 9,608 |  |  | $ | — |
Net investment contracts (b) |  | 3,036 |  |  | — |  |  | 3,036 |  |  | — |
Total assets at fair value |  | $ | 12,644 |  |  | $ | — |  |  | $ | 12,644 |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |  |
Deferred compensation plans (c) |  | $ | 10,636 |  |  | $ | — |  |  | $ | 10,636 |  |  | $ | — |
Foreign currency forward contracts (a) |  | 4,209 |  |  | — |  |  | 4,209 |  |  | — |
Net investment contracts (b) |  | 4,601 |  |  | — |  |  | 4,601 |  |  | — |
Total liabilities at fair value |  | $ | 19,446 |  |  | $ | — |  |  | $ | 19,446 |  |  | $ | — |

Page 19

Table of Contents
Nordson Corporation

October 31, 2022 |  | Total |  | Level 1 |  | Level 2 |  | Level 3
Assets: |  |  |  |  |  |  |  |
Foreign currency forward contracts (a) |  | $ | 5,035 |  |  | $ | — |  |  | $ | 5,035 |  |  | $ | — |
Total assets at fair value |  | $ | 5,035 |  |  | $ | — |  |  | $ | 5,035 |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |  |
Deferred compensation plans (b) |  | $ | 9,076 |  |  | $ | — |  |  | $ | 9,076 |  |  | $ | — |
Foreign currency forward contracts (a) |  | 11,724 |  |  | — |  |  | 11,724 |  |  | — |
Total liabilities at fair value |  | $ | 20,800 |  |  | $ | — |  |  | $ | 20,800 |  |  | $ | — |

(a)We enter into foreign currency forward contracts to reduce the risk of foreign currency exposures resulting from receivables, payables, intercompany receivables, intercompany payables and loans denominated in foreign currencies. Foreign exchange contracts are valued using market exchange rates. These foreign exchange contracts are not designated as hedges.
(b)Net assets of our foreign subsidiaries are exposed to volatility in foreign currency exchange rates. We utilize net investment hedges to offset the translation adjustment arising from re-measuring our investment in foreign subsidiaries. The notional amount of our net investment hedge contracts as of July 31, 2023 was $385,000.
(c)Executive officers and other highly compensated employees may defer up to 100% of their salary and annual cash incentive compensation and for executive officers, up to 90% of their long-term incentive compensation, into various non-qualified deferred compensation plans. Deferrals can be allocated to various market performance measurement funds. Changes in the value of compensation deferred under these plans are recognized each period based on the fair value of the underlying measurement funds.
The carrying amounts and fair values of financial instruments, other than cash and cash equivalents, receivables, and accounts payable, are shown in the table below. The carrying values of cash and cash equivalents, receivables and accounts payable approximate fair value due to the short-term nature of these instruments.

|  | July 31, 2023
|  | Carrying Amount |  | Fair Value
Long-term debt (including current portion) |  | $ | 838,098 |  |  | $ | 836,098 |

Long-term debt is valued by discounting future cash flows at currently available rates for borrowing arrangements with similar terms and conditions, which are considered to be Level 2 inputs under the fair value hierarchy. The carrying amount of long-term debt is shown net of unamortized debt issuance costs as disclosed in the Long-term Debt Note.
Derivative financial instruments
Foreign Currency Forward Contracts
We operate internationally and enter into intercompany transactions denominated in foreign currencies. Consequently, we are subject to market risk arising from exchange rate movements between the dates foreign currency transactions occur and the dates they are settled. We regularly use foreign currency forward contracts to reduce our risks related to most of these transactions. These contracts usually have maturities of 90 days or less and generally require us to exchange foreign currencies for U.S. dollars at maturity, at rates stated in the contracts. These contracts are not designated as hedging instruments under U.S. GAAP. Accordingly, the changes in the fair value of the foreign currency forward contracts are recognized in each accounting period in “Other – net” on the Condensed Consolidated Statements of Income together with the transaction gain or loss from the related balance sheet position.
For the three months ended July 31, 2023, we recognized a net loss of $93 on foreign currency forward contracts and a net loss of $885 from the change in fair value of balance sheet positions. For the three months ended July 31, 2022, we recognized a net gain of $15,181 on foreign currency forward contracts and a net loss of $14,436 from the change in fair value of balance sheet positions. For the nine months ended July 31, 2023, we recognized a net gain of $12,086 on foreign currency forward contracts and a net loss of $19,710 from the change in fair value of balance sheet positions. For the nine months ended July 31, 2022, we recognized a net gain of $2,503 on foreign currency forward contracts and a net loss of $394 from the change in fair value of balance sheet positions. The fair values of our foreign currency forward contract assets and liabilities are included in Receivable-net and Accrued liabilities, respectively, in our Consolidated Balance Sheets.
Page 20

Table of Contents
Nordson Corporation
The following table summarizes, by currency, the foreign currency forward contracts outstanding at July 31, 2023 and 2022:

July 31, 2023 contract amounts: |  | Notional Sell Amounts |  | Notional Buy Amounts
Euro |  | $ | 95,064 |  |  | $ | 194,850 |
British pound |  | 20,489 |  |  | 132,956 |
Japanese yen |  | 23,195 |  |  | 17,908 |
Mexican Peso |  | 3,227 |  |  | 28,158 |
Hong Kong dollar |  | 2,080 |  |  | 7,265 |
Singapore dollar |  | 60 |  |  | 19,817 |
Australian dollar |  | — |  |  | 9,236 |
Taiwan Dollar |  | — |  |  | 8,000 |
Others |  | 2,602 |  |  | 71,830 |
Total |  | $ | 146,717 |  |  | $ | 490,020 |
July 31, 2022 contract amounts: |  | Notional Sell Amounts |  | Notional Buy Amounts
Euro |  | $ | 88,275 |  |  | $ | 333,285 |
British pound |  | 36,779 |  |  | 78,942 |
Japanese yen |  | 16,688 |  |  | 37,163 |
Hong Kong dollar |  | — |  |  | 67,341 |
Singapore dollar |  | 378 |  |  | 18,025 |
Australian dollar |  | 278 |  |  | 9,426 |
Others |  | 26,012 |  |  | 98,113 |
Total |  | $ | 168,410 |  |  | $ | 642,295 |

We are exposed to credit-related losses in the event of nonperformance by counterparties to financial instruments. These financial instruments include cash deposits and foreign currency forward contracts. We periodically monitor the credit ratings of these counterparties in order to minimize our exposure. Our customers represent a wide variety of industries and geographic regions. For the three and nine months ended July 31, 2023 and 2022, there were no significant concentrations of credit risk.
Net Investment Hedges
Net assets of our foreign subsidiaries are exposed to volatility in foreign currency exchange rates. We may utilize net investment hedges to offset the translation adjustment arising from re-measuring our investment in foreign subsidiaries.
During the second quarter of 2023, the Company designated €180,000 of borrowings as a hedge of our net investment in certain foreign subsidiaries to mitigate the foreign exchange risk associated with certain investments in these subsidiaries. On June 30, 2023, the hedge was terminated. Any increase or decrease related to the remeasurement of the €180,000 borrowing into U.S. dollars was recorded in the currency translation component of Accumulated other comprehensive income (loss) within Shareholders' Equity in the Consolidated Balance Sheet. A gain of $1,144, net of tax, and a loss of $2,467, net of tax, was recorded on these net investment hedges for the three and nine months ended July 31, 2023, respectively.
During the quarter ended July 31, 2023, the Company entered into various cross currency swaps between the U.S. Dollar and Euro, Japanese Yen, Taiwan Dollar and Chinese Yuan which were designated as a hedges of our net investments in certain foreign subsidiaries to mitigate the foreign exchange risk associated with certain investments in these subsidiaries. Any increases or decreases related to the remeasurement of the hedges are recorded in the currency translation component of Accumulated other comprehensive income (loss) within Shareholders' Equity in the Consolidated Balance Sheet until the sale or substantial liquidation of the underlying investments. A loss of $1,205, net of tax, was recorded for both the three and nine months ended July 31, 2023.
Page 21

Table of Contents
Nordson Corporation
The following table summarizes the fair values of our net investment contracts designated as net investment hedges in the Company's Consolidated Balance Sheets as of July 31, 2023:

|  | Prepaid expenses and other current assets |  | Other assets |  | Accrued liabilities |  | Other long-term liabilities
Net investment contracts |  | $ | 2,977 |  |  | $ | 59 |  |  | $ | 841 |  |  | $ | 3,760 |

Long-term debt
A summary of long-term debt is as follows:

|  | July 31, 2023 |  | October 31, 2022
Revolving credit agreement, due 2028 |  | $ | 200,000 |  |  | $ | — |
Senior notes, due 2023-2025 |  | 32,000 |  |  | 55,500 |
Senior notes, due 2023-2027 |  | 54,286 |  |  | 71,429 |
Senior notes, due 2023-2030 |  | 260,000 |  |  | 350,000 |
Term loan due 2026 |  | 300,000 |  |  | — |
Euro Loan |  | — |  |  | 261,893 |
|  | 846,286 |  |  | 738,822 |
Less current maturities and notes payable |  | 110,643 |  |  | 392,537 |
Less unamortized debt issuance costs |  | 8,188 |  |  | 965 |
Long-term maturities |  | $ | 727,455 |  |  | $ | 345,320 |

Revolving credit agreement, due 2028 — In June 2023, we entered into a $1,150,000 unsecured multi-currency credit facility with a group of banks, which provides for a term loan facility in the aggregate principal amount of $300,000 (the "Term Loan Facility"), maturing in June 2026, and a multicurrency revolving credit facility in the aggregate principal amount of $850,000 (the "Revolving Facility"), maturing in June 2028 (the "New Credit Agreement"). The Company borrowed and has outstanding $300,000 on the Term Loan Facility on June 6, 2023. The Revolving Facility permits borrowing in U.S. Dollars, Euros, Sterling, Swiss Francs, Singapore Dollars, Yen, and each other currency approved by a Revolving Facility lender. The New Credit Agreement provides that the applicable margin for (i) RFR, as defined in the New Credit Agreement, and Eurodollar Loans will range from 0.85% to 1.20% and (ii) Base Rate Loans will range from 0.00% to 0.20%, in each case, based on the Company’s Leverage Ratio (as defined in the Credit Agreement and calculated on a consolidated net debt basis). Borrowings under the New Credit Agreement bear interest at (i) either a base rate or a SOFR rate, with respect to borrowings in U.S. dollars, (ii) a eurocurrency rate, with respect to borrowings in Euros and Yen, or (iii) Daily Simple RFR, with respect to borrowings in Sterling, Swiss Francs or Singapore Dollars, plus, in each case, an applicable margin (and, solely in the case of Singapore Dollars, a spread adjustment). The applicable margin is based on the Company’s Leverage Ratio. The weighted-average interest rate at July 31, 2023 was 6.00%.
Revolving credit agreement, due 2024 — In April 2019, we entered into a $850,000 unsecured multi-currency credit facility with a group of banks, which amended, restated and extended our then existing syndicated revolving credit agreement. This facility had a five-year term expiring in April 2024 and included a $75,000 subfacility for swing-line loans. On April 17, 2023, we entered into an amendment to, among other things, replace LIBOR with SOFR, EURIBOR, SONIA and TIBOR for U.S. Dollar, Euro, British Pound Sterling and Japanese Yen borrowings, respectively. On June 6, 2023, this credit agreement was terminated and replaced by the New Credit Agreement.
Senior notes, due 2023-2025 — These unsecured fixed-rate notes entered into in 2012 with a group of insurance companies have a remaining weighted-average life of 1.25 years. The weighted-average interest rate at July 31, 2023 was 3.10%.
Senior notes, due 2023-2027 — These unsecured fixed-rate notes entered into in 2015 with a group of insurance companies have a remaining weighted-average life of 2.23 years. The weighted-average interest rate at July 31, 2023 was 3.11%.
Senior notes, due 2023-2030 — These unsecured fixed-rate notes entered into in 2018 with a group of insurance companies have a remaining weighted-average life of 3.13 years. The weighted-average interest rate at July 31, 2023 was 3.97%.
Euro loan — The euro term loan facility with Bank of America Merrill Lynch International Limited was due in March 2023 and was repaid.
We were in compliance with all covenants at July 31, 2023, and the amount we could borrow would not have been limited by any debt covenants.
Page 22

Table of Contents
Nordson Corporation
Contingencies
We are involved in pending or potential litigation regarding environmental, product liability, patent, contract, employee and other matters arising from the normal course of business. Including the environmental matters discussed below, after consultation with legal counsel, we do not believe that losses in excess of the amounts we have accrued would have a material adverse effect on our financial condition, quarterly or annual operating results or cash flows.
Environmental
We have voluntarily agreed with the City of New Richmond, Wisconsin and other potentially responsible parties to share costs associated with the remediation of the City of New Richmond municipal landfill (the Site) and the construction of a potable water delivery system serving the impacted area down gradient of the Site. As of July 31, 2023 and October 31, 2022, our accrual for the ongoing operation, maintenance and monitoring obligation at th e Site was $266 a nd $266, respectively. The liability for environmental remediation represents management’s best estimate of the probable and reasonably estimable undiscounted costs related to known remediation obligations. The accuracy of our estimate of environmental liability is affected by several uncertainties such as additional requirements that may be identified in connection with remedial activities, the complexity and evolution of environmental laws and regulations, and the identification of presently unknown remediation requirements. Consequently, our liability could be greater than our current estimate. However, we do not expect that the costs associated with remediation will have a material adverse effect on our financial condition or results of operations.
Subsequent Event
On August 24, 2023, the Company completed the acquisition of the ARAG Group and its subsidiaries (ARAG Group or ARAG) pursuant to the terms of the Sale and Purchase Agreement, dated as of June 25, 2023, by and among the Company, its Italian subsidiary, Capvis Equity V LP (Capvis), DRIP Co-Investment (DRIP), and certain individuals (the Individual Sellers, and together with Capvis and DRIP, collectively, the Sellers). ARAG is a global market and innovation leader in the development, production and supply of precision control systems and smart fluid components for agricultural spraying. ARAG will operate as a division of our Industrial Precision Solutions segment. In anticipation of the acquisition, the Company entered into a €760,000 senior unsecured term loan facility with a group of banks in August 2023 (the Term F acility). The Term Facility has a 364-day term and matures in August 2024, and loans under the facility bear interest at a eurocurrency rate plus an applicable margin that will range from 1.1250% to 1.625% based on the Company’s Leverage Ratio (as defined in the term loan credit agreement and calculated on a consolidated net debt basis). The all-cash ARAG acquisition of approximately €957,000, net of the repayment of approximately €30,300 of debt of the acquired companies, was funded using the Term Facility and Revolving Facility. The financial results of the ARAG Group acquisition are not expected to have a material impact on our Consolidated Financial Statements.
Page 23

Table of Contents
Nordson Corporation
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following is management's discussion and analysis of certain significant factors affecting our financial condition and results of operations for the periods included in the accompanying condensed consolidated financial statements.
Overview
Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework to deliver top tier growth with leading margins and returns. The Company’s direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has approximately 7,200 employees with operations and support offices in over 35 countries.
COVID-19 Update
In December 2019, a novel strain of coronavirus (COVID-19) emerged and spread to other countries, including the United States. In March 2020, the World Health Organization declared COVID-19 as a pandemic (the COVID-19 pandemic). The COVID-19 pandemic, including multiple variants, resulted in governments around the world implementing stringent measures to help control the spread of the virus, including quarantines, “shelter in place” and “stay at home” orders, travel restrictions, business interruptions and other measures.
Although the World Health Organization declared an end to the COVID-19 pandemic on May 5, 2023, we continue to actively monitor the impact of COVID-19, which has negatively disrupted, and may continue to negatively disrupt, our business and results of operations in the future. For example, in the first quarter of 2023, our revenue growth in Asia-Pacific was negatively impacted by labor shortages and business disruption from the spread of COVID-19. The full extent of COVID-19 on our operations and the markets we serve remains uncertain and will depend largely on future developments related to COVID-19, including infection rates increasing or returning in various geographic areas, variations of COVID-19, actions by government authorities to contain the outbreak or treat its impact, such as reimposing previously lifted measures or putting in place additional restrictions, and the widespread distribution and acceptance of an effective vaccine, among other things. Future developments regarding COVID-19 and its effects cannot be accurately predicted.
Acquisitions
On August 24, 2023, the Company completed the acquisition of the ARAG Group and its subsidiaries (ARAG Group or ARAG) pursuant to the terms of the Sale and Purchase Agreement, dated as of June 25, 2023, by and among the Company, its Italian subsidiary, Capvis Equity V LP (Capvis), DRIP Co-Investment (DRIP), and certain individuals (the Individual Sellers, and together with Capvis and DRIP, collectively, the Sellers). ARAG is a global market and innovation leader in the development, production and supply of precision control systems and smart fluid components for agricultural spraying. ARAG will operate as a division of our Industrial Precision Solutions segment. In anticipation of the acquisition, the Company entered into a €760,000 senior unsecured term loan facility with a group of banks in August 2023 (the Term F acility). The Term Facility has a 364-day term and matures in August 2024, and loans under the facility bear interest at a eurocurrency rate plus an applicable margin that will range from 1.1250% to 1.625% based on the Company’s Leverage Ratio (as defined in the term loan credit agreement and calculated on a consolidated net debt basis). The all-cash ARAG acquisition of approximately €957,000, net of the repayment of approximately €30,300 of debt of the acquired companies, was funded using the Term Facility and Revolving Facility. The financial results of the ARAG Group acquisition are not expected to have a material impact on our Consolidated Financial Statements.
On November 3, 2022, the Company completed the acquisition of CyberOptics Corporation (CyberOptics) pursuant to the terms of the Agreement and Plan of Merger, dated as of August 7, 2022, by and among the Company, Meta Merger Company and CyberOptics. CyberOptics is a leading global developer and manufacturer of high-precision 3D optical sensing technology solutions. The CyberOptics acquisition expanded our test and inspection platform, providing differentiated technology that expands our product offering in the semiconductor and electronics industries and will be reported in our Advanced Technology Solutions segment. The all-cash transaction of approximately $378,000, net of cash acquired, was funded using borrowings under our revolving credit facility and cash on hand and is not expected to have a material impact on our Consolidated Financial Statements.
Critical Accounting Policies and Estimates
A comprehensive discussion of the Company’s critical accounting policies and management estimates and significant accounting policies followed in the preparation of the financial statements is included in Item 7 of our Annual Report on Form 10-K for the year ended October 31, 2022 (the 2022 Form 10-K). There have been no significant changes in critical accounting policies, management estimates or accounting policies followed since the year ended October 31, 2022.
Page 24

Table of Contents
Nordson Corporation
Results of Operations
Three months ended July 31, 2023
Worldwide sales for the three months ended July 31, 2023, were $648,677, a decrease of 2.0% from sales of $662,128 for the comparable period of 2022. The decrease consisted of a 4.5% decrease in organic sales, which was partially offset by a 2.4% increase due to an acquisition and a favorable effect from currency translation of 0.1%. The organic sales decrease was driven by ongoing pressure in electronics, primarily semiconductor dispense applications, and biopharma end markets, offset by strong growth in medical interventional solutions and polymer processing product lines.
In the Americas region, sales were $290,515 for the three months ended July 31, 2023, an increase of 4.1% from the comparable period of 2022, consisting of an organic sales increase of 2.2%, an increase due to an acquisition of 1.2%, and favorable currency effects of 0.7%. In the Asia Pacific region, sales were $190,626, a decrease of 17.6% from the comparable period of 2022, consisting of an organic sales decrease of 20.0% and unfavorable currency effects of 1.9%, partially offset by a 4.3% increase due to an acquisition. In Europe, sales were $167,536, an increase of 10.5% from the comparable period of 2022, consisting of an organic sales increase of 5.7%, favorable currency effects of 3.4%, and a 1.4% increase due to an acquisition.
Cost of sales for the three months ended July 31, 2023 were $288,357, down from $296,544 in the comparable period of 2022. Gross profit, expressed as a percentage of sales, increased to 55.5% from 55.2% in the comparable period of 2022. The 0.3 improvement was primarily driven by improved manufacturing efficiency and price realization offset by severance-related cost structure simplification actions.
Selling and administrative expenses for the three months ended July 31, 2023 were $189,324, up from $180,666 in the comparable period of 2022. The 4.8% increase was primarily driven by the first-year effect of an acquisition and related acquisition costs, partially offset by lower base business and incentive costs.
Operating profit decreased to $170,996 for the three months ended July 31, 2023, compared to $184,918 in the comparable period of 2022. Operating profit as a percentage of sales decreased to 26.4% f or the three months ended July 31, 2023, compared to 27.9% in the comparable period of 2022. The 1.5 percentage point decline in operating margin was primarily driven by lower sales volume and acquisition related costs.
Interest expense for the three months ended July 31, 2023 was $12,089, compared to $5,737 in the comparable period of 2022. The increase, compared to the prior year period, was primarily due to higher average debt levels, partially due to the CyberOptics acquisition, as well as increases in interest rates. Other income was $2,542 compared to $752 in the comparable period of 2022. Included in 2023 other income were pension and postretirement income of $1,343 and $886 of foreign currency losses. Included in 2022 other expense were pension and postretirement costs of $25 and $745 in foreign currency gains.
Net income for the three months ended July 31, 2023 was $127,891, or $2.22 per diluted share, compared to $141,811, or $2.45 per diluted share, in the same period of 2022. This represents a 9.8% decrease in net income, and a 9.4% decrease in diluted earnings per share. The decrease in income was driven by lower operating profit and increased interest expense.
Industrial Precision Solutions
Sales of the Industrial Precision Solutions segment were $338,257 in the three months ended July 31, 2023, a decrease of 0.9% from sales of $341,215 for the comparable period of 2022. The decrease consisted of an organic sales decrease of 1.5%, which was partially offset by favorable currency effects of 0.6%. The organic sales decrease was driven primarily by our product assembly and nonwovens product lines in Asia Pacific, partially offset by continued strength in the polymer processing product lines.
Operating profit as a percentage of sales decreased to 34.1% for the three months ended July 31, 2023, compared to 35.1% in the comparable period of 2022. The 1.0 percentage point decline in operating margin was primarily driven by lower sales volume and unfavorable sales mix.
Medical and Fluid Solutions
Sales of the Medical and Fluid Solutions segment were $170,871 in the three months ended July 31, 2023, a decrease of 3.9% from sales of $177,840 for the comparable period of 2022. The decrease consisted of an organic sales decrease of 3.9%, which was driven by continued softness in the medical fluid components and fluid solutions product lines, partially offset by strong double-digit demand for medical interventional solutions product lines.
Operating profit as a percentage of sales decreased to 31.6% for the three months ended July 31, 2023, compared to 32.7% in the comparable period of 2022. T he 1.1 percentage point decline in operating margin was primarily due to lower sales volume and sales mix changes within medical product lines.
Page 25

Table of Contents
Nordson Corporation
Advanced Technology Solutions
Sales of the Advanced Technology Solutions segment were $139,549 in the three months ended July 31, 2023, a decrease of 2.5% from sales of $143,073 for the comparable period of 2022. The decrease consisted of an organic sales decrease of 12.8% and unfavorable currency effects of 0.4%, partially offset by a 10.7% increase due to an acquisition. The organic sales decrease was driven by electronics dispense products serving semiconductor end markets, predominantly in Asia Pacific, slightly offset by continued growth in test and inspection product lines.
Operating profit as a percentage of sales decreased to 19.4% for the three months ended July 31, 2023, compared to 19.7% in the comparable period of 2022. T he 0.3 percentage point decline in operating margin was driven by severance costs, partially offset by favorable sales mix and realization of cost savings actions.
Nine months ended July 31, 2023
Worldwide sales for the nine months ended July 31, 2023 were $1,909,319, an increase of 0.1% from sales of $1,906,697 for the comparable period of 2022. The increase consisted of a 2.6% increase due to an acquisition, substantially offset by unfavorable currency translation effects of 1.8% and a 0.7% decrease in organic sales volume. Strength in the polymer processing and medical interventional solutions product lines was offset by weakness in the electronic dispense, fluid solutions, and medical fluid components product lines.
In the Americas region, sales were $834,125 for the nine months ended July 31, 2023, an increase of 5.2% from the comparable period of 2022, consisting of an organic sales increase of 3.2%, an increase due to an acquisition of 1.9%, and a favorable effect from currency translation of 0.1%. In the Asia Pacific region, sales were $576,815, a decrease of 9.0% from the comparable period of 2022, consisting of an organic sales decrease of 9.7% and a 3.7% decrease from unfavorable currency translation effects, partially offset by a 4.4% increase due to an acquisition. In Europe, sales were $498,379, an increase of 3.9% from the comparable period of 2022, consisting of an organic sales increase of 4.3% and a 1.6% increase due to an acquisition, partially offset by unfavorable currency effects of 2.0%.
Cost of sales for the nine months ended July 31, 2023 were $868,007, up from $843,344 in the comparable period of 2022. Gross profit, expressed as a percentage of sales, decreased to 54.5% from 55.8% in the comparable period of 2022. The 1.3 percentage point decrease in gross margin was driven by reduced manufacturing efficiency and severance in sites dealing with meaningful volume decreases and incremental inventory step-up amortization of $2,743 incurred in the first quarter of 2023 compared to 2022.
Selling and administrative expenses for the nine months ended July 31, 2023 were $553,590, up from $538,602 in the comparable period of 2022. The 2.8% increase was primarily driven by the first-year effect of an acquisition and acquisition related costs, partially offset by favorable currency translation effects and lower incentive costs.
Operating profit decreased to $487,722 for the nine months ended July 31, 2023, compared to $524,751 in the comparable period of 2022. Operating profit as a percentage of sales decreased to 25.5% f or the nine months ended July 31, 2023, compared to 27.5% in the comparable period of 2022. The 2.0 percentage point decline in operating margin was primarily driven by unfavorable sales mix, and a combination of fees, severance, and non-cash inventory charges associated with the CyberOptics and ARAG Group acquisitions.
Interest expense for the nine months ended July 31, 2023 was $32,532, compared to $16,748 in the comparable period of 2022. The increase, compared to the prior year period, was primarily due to higher average debt levels, partially due to the CyberOptics acquisition, as well as increases in interest rates. Other expense was $2,059 compared to $37,720 in the comparable period of 2022. Included in 2023 other expense were pension income of $4,044 and $7,625 in foreign currency losses. Included in 2022 other expense were non-cash pension settlement charges of $41,221 related to the purchase of an annuity contract to relieve the Company of certain pension benefit obligations, other pension and postretirement income of $1,002 and $2,109 in foreign currency gains.
Net income for the nine months ended July 31, 2023 was $359,715, or $6.24 per diluted share, compared to $371,854, or $6.37 per diluted share, in the same period of 2022. This represents a 3.3% decrease in net income, and a 2.0% decrease in diluted earnings per share. Net income for the nine months ended July 31, 2022 included after tax non-cash pension settlement charges of $32,450, or $0.56 per diluted share, related to the purchase of an annuity contract to relieve the Company of certain pension benefit obligations. Excluding the prior year pension settlement charges, the decrease was driven primarily by a combination of lower margins; fees, severance and non-cash inventory charges associated with the CyberOptics and ARAG Group acquisitions and higher interest expense.
Page 26

Table of Contents
Nordson Corporation
Industrial Precision Solutions
Sales of the Industrial Precision Solutions segment were $985,610 in the nine months ended July 31, 2023, an increase of 0.4% from sales of $981,582 for the comparable period of 2022. The increase consisted of an organic sales increase of 2.6%, partially offset by unfavorable currency effects that decreased sales by 2.2%. The organic sales increase was driven primarily by strong demand in polymer processing product lines.
Operating profit as a percentage of sales increased to 33.4% for the nine months ended July 31, 2023, compared to 33.0% in the comparable period of 2022. The 0.4 percentage point improvement in operating margin was primarily due to non-recurring inventory step-up amortization incurred in the first quarter of 2022 compared to 2023.
Medical and Fluid Solutions
Sales of the Medical and Fluid Solutions segment were $491,683 in the nine months ended July 31, 2023, a decrease of 3.4% from sales of $508,836 for the comparable period of 2022. The decrease consisted of an organic sales decrease of 2.4% and unfavorable currency effects that decreased sales by 1.0%. The organic sales decrease was driven by lower demand for the medical fluid components and fluid solutions product lines, partially offset by strong demand for medical interventional solutions product lines.
Operating profit as a percentage of sales decreased to 28.7% for the nine months ended July 31, 2023, compared to 32.5% in the comparable period of 2022. T he 3.8 percentage point decline in operating margin was primarily due to meaningful sales mix changes within medical product lines and related factory inefficiencies due to reduced volumes.
Advanced Technology Solutions
Sales of the Advanced Technology Solutions segment were $432,026 in the nine months ended July 31, 2023, an increase of 3.8% from sales of $416,279 for the comparable period of 2022. The increase was the result of a 12.2% increase due to an acquisition, partially offset by an organic sales volume decrease of 6.6% and unfavorable currency effects of 1.8%. The organic sales decrease was driven by lower demand in electronic dispense product lines, partially offset by stronger demand in test and inspection product lines.
Operating profit as a percentage of sales decreased to 16.2% for the nine months ended July 31, 2023, compared to 22.9% in the comparable period of 2022. T he 6.7 percentage point decline in operating margin was primarily due to fees, severance and non-cash inventory charges of $10,295 associated with the CyberOptics acquisition incurred in the first quarter of 2023 and factory inefficiencies due to reduced volumes.
Income taxes
We record our interim provision for income taxes based on our estimated annual effective tax rate, as well as certain items discrete to the current period. Significant judgment is involved regarding the application of global income tax laws and regulations and when projecting the jurisdictional mix of income. We have considered several factors in determining the probability of realizing deferred income tax assets which include forecasted operating earnings, available tax planning strategies and the time period over which the temporary differences will reverse. We review our tax positions on a regular basis and adjust the balances as new information becomes available. The effective tax rate for the three and nine months ended July 31, 2023 was 21.1% and 20.9%, respectively, compared to 21.4% and 21.2% for the three and nine months ended July 31, 2022, respectively.
Due to our share-based payment transactions, our income tax provision included a discrete tax benefit of $996 and $2,745 for the three months and nine months ended July 31, 2023, respectively, compared to $115 and $1,539 for the three and nine months ended July 31, 2022, respectively.
Foreign Currency Effects
In the aggregate, average exchange rates for 2023 used to translate international sales and operating results into U.S. dollars were generally unfavorable compared with average exchange rates existing during 2022. It is not possible to precisely measure the impact on operating results arising from foreign currency exchange rate changes, because of changes in selling prices, sales volume, product mix and cost structure in each country in which we operate. However, if transactions for the three months ended July 31, 2023 were translated at exchange rates in effect during the same period of 2022, we estimated that sales would have been approximately $4,000 lower while costs of sales and selling and administrative expenses would have been approximately $3,000 lower. If transactions for the nine months ended July 31, 2023 were translated at exchange rates in effect during the same period of 2022, we estimated that sales would have been approximately $35,000 higher while costs of sales and selling and administrative expenses would have been approximately $23,000 higher.
Page 27

Table of Contents
Nordson Corporation
Financial Condition
Liquidity and Capital Resources
During the nine months ended July 31, 2023, cash and cash equivalents decreased $20,319. Cash provided by operations during this period was $478,072 compared to $339,691 for the nine months ended July 31, 2022. Changes in operating assets and liabilities increased cash by $19,197 in the nine months ended July 31, 2023 and decreased cash by $162,333 in the comparable period of 2022, driven primarily by improvements in accounts receivable and inventory, as well as cash inflows related to settlement of foreign exchange contracts.
Cash used in investing activities was $401,996 for the nine months ended July 31, 2023, compared to $210,571 used in the comparable period of 2022. During the nine months ended July 31, 2023, cash of $377,843 was used for the CyberOptics acquisition and cash of $24,244 was used for capital expenditures. During the nine months ended July 31, 2022, cash of $171,613 was used for the NDC acquisition and $39,373 was used for capital expenditures.
Cash used in financing activities was $102,074 for the nine months ended July 31, 2023, compared to $294,418 in the comparable period of 2022. In the nine months ended July 31, 2023, cash of $111,547 was used for dividend payments and cash of $78,163 was used for the purchase of treasury shares, versus $88,675 and $233,767, respectively, in the comparable period of 2022. The nine months ended July 31, 2023 included net borrowings of long-term debt of $73,956, used primarily to fund the acquisition of CyberOptics, compared to net borrowings of $22,905 during the nine months ended July 31, 2022.
The following is a summary of significant changes in balance sheet captions from October 31, 2022 to July 31, 2023. Inventories-net increased by $56,343, primarily as a result of the CyberOptics acquisition. Goodwill and intangibles increased by $279,630 and $58,600, respectively, due to the CyberOptics acquisition. Accrued liabilities decreased by $37,193 due primarily to incentive compensation payments made in the nine months ended July 31, 2023, and long-term debt increased principally as result of refinancing activities completed in 2023.
We believe the combination of present and expected capital resources, cash from operations and unused financing sources, such as our credit facilities, which includes our revolving credit agreement entered in June 2023 and the 364-day term loan facility utilized to fund the ARAG Group acquisition, are more than adequate to meet cash requirements for the next twelve months and for the foreseeable future thereafter. There are no significant restrictions limiting the transfer of funds from international subsidiaries to the parent Company. We were in compliance with all debt covenants as of July 31, 2023. Refer to our Long-term debt and Subsequent Event Notes in the notes to our condensed consolidated financial statements for additional details regarding our debt outstanding and Term Facility.
Safe Harbor Statements Under the Private Securities Litigation Reform Act of 1995
This Form 10-Q, particularly “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements relate to, among other things, income, earnings, cash flows, changes in operations, operating improvements, businesses in which we operate and the United States and global economies. Statements in this quarterly report that are not historical are hereby identified as “forward-looking statements” and may be indicated by words or phrases such as “anticipates,” “supports,” “plans,” “projects,” “expects,” “believes,” “should,” “would,” “could,” “hope,” “forecast,” “management is of the opinion,” use of the future tense and similar words or phrases. These statements reflect management’s current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions including the Company’s ability to complete and successfully integrate acquisitions, including the integration of CyberOptics and ARAG; the Company’s ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, including the conflict between Russia and Ukraine and tensions between the United States and China, acts of terror, natural disasters and pandemics, including the recent COVID-19 pandemic.
In light of these risks and uncertainties, actual events and results may vary significantly from those included in or contemplated or implied by such statements. Readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Factors that could cause actual results to differ materially from the expected results are discussed in Part I, Item 1A, Risk Factors in our 2022 Form 10-K.
Page 28

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Information regarding our financial instruments that are sensitive to changes in interest rates and foreign currency exchange rates was disclosed under Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” in our 2022 Form 10-K. The information disclosed has not changed materially in the interim period since then.
ITEM 4. CONTROLS AND PROCEDURES
Our management with the participation of the principal executive officer (President and Chief Executive Officer) and principal financial officer (Executive Vice President, Chief Financial Officer) has reviewed and evaluated our disclosure controls and procedures (as defined in the Securities Exchange Act Rule 13a-15(e)) as of July 31, 2023. Based on that evaluation, our management, including the principal executive and financial officers, has concluded that our disclosure controls and procedures were effective as of July 31, 2023 in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
There were no changes in our internal control over financial reporting that occurred during the three months ended July 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Page 29

Table of Contents
Nordson Corporation
Part II – OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
See our Contingencies Note to the condensed consolidated financial statements for a discussion of our contingencies and legal matters.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this quarterly report, you should carefully consider the risk factors disclosed in “Item 1A. Risk Factors” of our 2022 Form 10-K.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The following table summarizes common shares repurchased by the Company during the three months ended July 31, 2023:

(In whole shares) |  | Total Number of Shares Purchased (1) |  | Average Price Paid per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2) |  | Maximum Value of Shares that May Yet Be Purchased Under the Plans or Programs (2)
May 1, 2023 to May 31, 2023 |  | 99,982 |  |  | $ | 216.65 |  |  | 99,823 |  |  | $ | 563,389 |
June 1, 2023 to June 30, 2023 |  | 7,717 |  |  | $ | 218.53 |  |  | 7,455 |  |  | $ | 561,762 |
July 1, 2023 to July 31, 2023 |  | 905 |  |  | $ | 240.73 |  |  | — |  |  | $ | 561,762 |
Total |  | 108,604 |  |  |  |  | 107,278 |  |  |

(1) Includes shares tendered for taxes related to stock option exercises and vesting of restricted stock.
(2) In December 2014, the board of directors authorized a $300,000 common share repurchase program. In August 2015, the board of directors authorized the repurchase of up to an additional $200,000 of the Company’s common shares. In August 2018, the board of directors authorized the repurchase of an additional $500,000 of the Company’s common shares. In September 2022, the board of directors authorized the repurchase of up to an additional $500,000 of the Company's common shares. Approximately $561,762 of the total $1,500,000 authorized remained available for share repurchases at July 31, 2023. Uses for repurchased shares include the funding of benefit programs including stock options and restricted stock. Shares purchased are treated as treasury shares until used for such purposes. The repurchase program will be funded using cash from operations and proceeds from borrowings under our credit facilities. The repurchase program does not have an expiration date.
ITEM 5. OTHER INFORMATION
On June 30, 2023, Stephen P. Lovass, an Executive Vice President of the Company, adopted a trading arrangement for the sale of the Company’s common shares (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Lovass’s Rule 10b5-1 Trading Plan, which expires no later than March 28, 2024, provides for the sale of up to 6,898 common shares pursuant to the terms of the Rule 10b5-1 Trading Plan.
Page 30

Table of Contents
Nordson Corporation

ITEM 6. | EXHIBITS

4.1 | Credit Agreement, dated as of June 6, 2023, by and among Nordson Corporation and Nordson Engineering GmbH, as Borrowers, Wells Fargo Bank, National Association, as Agent, and Wells Fargo Securities, LLC, BofA Securities, Inc., JPMorgan Chase Bank, N.A., PNC Capital Markets LLC, and U.S. Bank National Association, as Joint Lead Arrangers and Bookrunners, and various financial institutions named therein as lenders. (incorporated herein by reference to Exhibit 4.1 to Registrant’s Form 8-K dated June 6, 2023)
31.1 | Certification pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 by the Chief Executive Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 | Certification pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 by the Chief Financial Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
101 | The following financial information from Nordson Corporation’s Quarterly Report on Form 10-Q for the three and nine months ended July 31, 2023 formatted in inline Extensible Business Reporting Language (iXBRL): (i) the Condensed Consolidated Statements of Income for the three and nine months ended July 31, 2023 and 2022, (ii) the Consolidated Statements of Comprehensive Income for the three and nine months ended July 31, 2023 and 2022, (iii) the Consolidated Balance Sheets at July 31, 2023 and October 31, 2022, (iv) the Consolidated Statements of Shareholders’ Equity for the three and nine months ended July 31, 2023 and 2022, (v) the Condensed Consolidated Statements of Cash Flows for the nine months ended July 31, 2023 and 2022, and (vi) the Notes to Condensed Consolidated Financial Statements.
104 | The cover page from Nordson Corporation’s Quarterly Report on Form 10-Q for the quarter ended July 31, 2023, formatted in inline Extensible Business Reporting Language (iXBRL) (included in Exhibit 101).

Page 31

Table of Contents
Nordson Corporation
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 24, 2023 | Nordson Corporation
| By: /s/ Joseph P. Kelley
| Joseph P. Kelley
| Executive Vice President, Chief Financial Officer
| (Principal Financial Officer)

Page 32